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ABSTRACT
Alzheimer’s disease (AD) is accompanied by abnormal extracellular deposition of
amyloid  (A) peptide. This has led to the amyloid cascade hypothesis, causatively
relating A with AD. While A deposits assume a fibrillar cross- structure, prefibrillar
oligomers of A have been identified as the main cytotoxic agents in AD.
Pyroglutamylated amyloid beta (ApE) peptides are N-terminally truncated and
pyroglutamylated (at Glu3 or Glu11) A molecules that display enhanced cytotoxicity
and represent up to 50% of total A in AD brains. ApE significantly enhances the
toxicity of unmodified A by an unknown mechanism. Although in situ A populations
are heterogeneous, the majority of studies have been conducted on single A species.
Here, we examined the structural and morphological changes that occur in mixed
A/ApE samples. Circular dichroism and transmission electron microscopy data
indicate that ApE3-42 forms -sheet structure and undergoes delayed fibrillogenesis
compared to unmodified A1-42. Further, ApE3-42 decelerates -sheet formation in mixed
A1-42/ApE3-42 samples. FTIR measurements, using 13C-labeled A1-42 and unlabeled
ApE3-42, indicate that ApE3-42 inhibits cross--sheet formation by A1-42, which explains
the retardation of fibrillogenesis. FTIR on peptides 13C-labeled at specific segments
provided site specific structural information. Based on these data, the monomeric A
structure has been modeled as a -hairpin stabilized by intramolecular H-bonding with an
iii

N-terminal -helix. These hairpins likely form higher order aggregates through ionic and
hydrophobic interactions between the C-terminus of one hairpin and the N-terminus of
another. Utilizing a novel technique, hydration from gas phase, we examined the -helix
to -sheet transitions of these peptides. When combined, ApE3-42 and A1-42 mutually
inhibit intermolecular -sheet formation, instead promoting formation of ApE3-42/A1-42
hetero-oligomers of intramolecular H-bonding.
These hetero-oligomers displayed enhanced toxicity to PC12 cells compared to
individual peptides and induced greater calcium release from lipid vesicles than
unmodified A. These results indicate that A and ApE mutually inhibit fibrillogenesis
and stabilize hetero-oligomers of enhanced cytotoxicity, possibly through a membrane
permeabilization mechanism. Collectively, our findings lead to a new concept that
A/ApE hetero-oligomers, not just A or ApE oligomers, are the main cytotoxic
species in AD.
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CHAPTER ONE: INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenerative disease affecting more than 35 million
people worldwide. The primary symptom of AD is progressive loss of memory and other cognitive
faculties leading to death within 3-9 years of diagnoses (1). AD is the most common form of
dementia representing over 50% of cases examined at autopsy or clinical series (1). AD primarily
affects the elderly. The odds of being diagnosed with AD double every 5 years after the age of 65,
and the odds of receiving a positive diagnosis after the age of 85 is 1:3 (2). Due to an aging
population, the number of cases of AD in the United States is rising rapidly. By 2050 there will be
an estimated 13 million cases representing a yearly economic cost of $1 trillion (3).
Effective treatments for AD are lacking and the success rate of AD drugs in clinical trials
falls below 1% (4). There is significant loss of neuronal synapses in AD correlating closely with
cognitive symptoms and predating neuronal death (5). Familial Alzheimer disease (FAD) is caused
by genetic mutation with symptoms generally appearing in the early 40s. Sporadic Alzheimer
disease (SAD), which makes up the majority of AD cases, usually manifests after the age of 65.
FAD and SAD are indistinguishable from one another histologically. The two main hallmarks of
AD are beta amyloid plaques and neurofibrillary tangles (NFTs). Plaques are extracellular protein
aggregates composed of the A peptide; NFTs are intracellular aggregates consisting largely of
hyper-phosphorylated tau. A peptides are small, hydrophobic peptides of no known physiological
function, while tau normally associates with microtubules.
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The amyloid cascade hypothesis states that AD is a consequence of the buildup of A
peptides, through either increased production or decreased clearance (6). Evidence points to
soluble aggregates of A as the cytotoxic species in AD (7, 8).

Amyloid Beta Peptide
A peptides are formed by cleavage of the amyloid precursor protein (APP) a
transmembrane glycoprotein. The N-terminus of the APP is in extracellular space, while the Cterminus terminates within the cytosol. The exact function of the APP is unknown, but it is believed
to play a role in cell growth and proliferation, as well as influencing synaptogenesis (9). In the
non-amyloidogenic pathway, the APP is cleaved by -secretase in the middle of the amyloid beta
transmembrane segment creating the C83 fragment. The C83 fragment is then cleaved by secretase forming the APP Intracellular Domain (AICD) and a truncated A fragment known as
p3 (9-11). The AICD enters the cytosol and is believed to play a role in nuclear signaling while
the p3 seems pathologically irrelevant. Interaction between -secretase and the APP can lead to
amyloidogenic cleavage at D672 freeing the N-terminus of the A and creating the C99 fragment
(12). The C99 fragment is then cleaved by -secretase freeing the A peptide and forming the
AICD (8, 10). This cleavage most frequently occurs at V40 forming the A40 fragment, but
cleavage also occurs at nearby A42 and G38 positions on the C99 forming the A42 and A1-38
respectively (12-14). The A peptide leaves the membrane and enters the extracellular space
2

following cleavage (10, 11, 14). Most mutations associated with FAD are associated with A
production and involve the APP or its processing (15-19). There are many different species of A
peptide and in situ A populations are heterogeneous (13, 20). Although the most common A
found in the brain is the A1-40 the A1-42 is most often associated with AD (13, 21). Additionally,
pyroglutamylated A is a major species in the AD brain and has been found to make up to 50% of
the soluble A load (13, 20, 22). Amyloid beta builds up intracellularly as well, through production
at either the endoplasmic reticulum (ER) or vesicles, as well as re uptake of oligomers (23-26).
The intracellular buildup of A often precedes extracellular increases in A concentration and
onset of synaptic dysfunction (24, 25).

Current Issues in AD
No current treatments exist that delay the progression of AD. Currently, five drugs are FDA
approved for the treatment of AD, the cholinesterase inhibitors: Tacrine, Donepezil, Revastigmine,
and Galantamine; and the N-methyl-D-aspartate (NMDA) receptor antagonist Memantine. There
have been no new AD drugs approved since 2003 (4). Between 2002 and 2012, only one of the
230 compounds assessed for the treatment of AD passed phase 3 clinical trials and was approved
for treatment(4). This failure rate of 99.6% is the highest of any therapeutic area (27, 28). High
profile AD drug failures include the anti A monoclonal antibody drugs bapineuzumab and
solanezumab. As well as the A reducing drugs Phenserine, which reduces APP expression (29),
3

and Flurizan, which reduces A1-42 levels, likely through a mechanism involving -secretase (30,
31). Data has not been released as to whether these drugs failed to have an effect on A load, or
whether they decreased A load, but there was no corresponding decrease in cognitive decline.
The failure of these drugs to translate from animal models into humans calls into question the
accuracy of existing AD models and necessitates re-evaluation of the amyloid cascade hypothesis.

Shortcomings of the Amyloid Cascade Hypothesis
In the decades since the amyloid cascade hypothesis was first postulated, many new
discoveries have been made. (32-35). Recent findings have shifted focus from insoluble fibrils to
soluble oligomers of A as the main cytotoxic entity in AD. Soluble oligomers of A have been
shown to inhibit long-term potentiation (LPT), and the population of soluble oligomers is an
accurate predictor of synaptic decline (7, 8, 23, 36-39). Additionally, plaque levels do not correlate
with disease state and are found in the brains of cognitively normal patients (40, 41). In fact,
cognitive impairment in AD correlates better with tangle burden than plaque levels (42).
Additionally, studies have found A neurotoxicity to be tau dependent, both in vivo and in vitro
casting doubt on the completeness of the amyloid cascade hypothesis (43-45). Studies have shown
oligomers to be significantly more cytotoxic than fibrils (46, 47). Some of these oligomers may be
intermediates of fibrillogenesis, however others are formed via distinct pathways (48, 49).
Neurotoxic oligomers appear to propagate via a prion-like mechanism, with pyroglutamylated
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amyloid beta (ApE) in particular having a profound effect on toxicity even at low molar ratios
(44, 50, 51). Dot blot experiments have shown that hybrid ApE3-42:A1-42 oligomers and similar
sized oligomers formed by A1-42 alone are distinct structurally with hybrid oligomers having
significantly enhanced toxicity (44). Surprisingly, A monomers appear neuroprotective, against
both oxidative stress as well as the absence of insulin (52, 53). A40 has demonstrated a protective
effect by inhibition of A1-42 aggregation (52). These findings necessitate the altering of the
amyloid cascade hypothesis, shifting focus from large fibrillar aggregates to small soluble
oligomers of A. An illustration of this refined amyloid cascade where oligomers formed as
intermediates during fibrillogenesis or via other aggregation pathways lead to AD is shown in
Figure 1. Little is known about the A peptide following cleavage from the membrane and prior
to formation of proto-fibrils.
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Figure 1. Potential pathway for the pathogenesis of AD via A oligomers. Little is known about the aspects of this
pathway contained within the blue box.

Pyroglutamylated Amyloid Beta
The N-truncated, N-modified pyroglutamylated A (ApE) is a major A species in the
AD brain and can make up as much as 50% of total soluble A load (13, 20, 22, 54).
Pyroglutamylation occurs when glutamic acid is at the N-terminus of the peptide, most often due
to upstream aminopeptidase degradation. The N-terminal glutamic acid is then cyclized in a
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dehydration reaction carried out via glutaminyl cyclase (QC) (55). Pyroglutamylated A are
believed to be highly involved in the pathogenesis of AD (20, 44, 54, 56). A population changes
over time with the fraction of ApE increasing with disease progression (20, 57). In addition, QC
expression is found in the peripheral blood of AD patients (58). The most common ApE is the
ApE3-42 fragment, however ApE11-42, ApE3-40, and ApE11-40 have all been observed in AD brains
(20, 59, 60).
Over expression of QC in mice was found to cause behavioral deficits while knockout or
inhibition of QC had a rescue effect (55, 61). Loss of calcium homeostasis, an early event in AD,
has been shown to increase QC expression leading to an increased in ApE production (62).
Studies indicate that ApE has altered aggregation, forming greater numbers and longer lived
oligomers compared to unmodified A (63, 64). Pyroglutamylated A and hybrid A1-42/ApE3-42
oligomers display increased toxicity when compared to unmodified A (44, 56). Additional studies
found ApE to be more resistant to astrocyte degradation and have increased cytotoxicity to
cultured neurons compared to both A1-42 and A1-40 (22). A correlation between ApE and
adjacent deposits of hyper-phosphorylated tau has been found in AD brains, providing evidence
of a link between ApE and tau phosphorylation (56). This is strong evidence towards the
involvement of ApE in AD.
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Gaps in Knowledge of A Oligomers
Although they are believed to be the cytotoxic species in A, structural data on A
oligomers is lacking. Previous structural studies have often used non-physiological conditions
calling into question the disease relevance of their results (65, 66). Additionally, most structural
studies have taken place on a single species of A and not a heterogeneous population as is found
in situ. More detailed structural understandings of A oligomers and early aggregates are
necessary to better understand the role of these oligomers in the pathogenesis of AD. Of particular
interest are the changes that occur in mixed samples of ApE and A. This work aimed to
characterize structural and morphological changes exerted on A by ApE. We found that ApE
and A mutually inhibit fibrillogenesis by inhibiting intermolecular -sheet formation of one
another. Instead, in combination they form hetero-oligomers composed of -hairpins which
aggregate through ionic or hydrophobic bonds of a C-terminus of one hairpin and the N-terminus
of another. These hetero-oligomers had increased cytotoxicity to PC12 cells. This study highlights
the importance of A: ApE hetero-oligomers in the pathogenesis of AD. These hetero-oligomers
may represent a promising target in the search for promising new ways to effectively treat AD.
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CHAPTER TWO: LITERATURE SEARCH
Before moving forward with this project, it was necessary to re-evaluate the amyloid
cascade hypothesis to ensure the pertinence of A peptides in AD. Research was conducted on the
genetics of AD, as well as the role tau plays in AD. This data supports A peptides as the initiator
of AD pathology. In addition, current literature was searched on the structure and aggregation of
A, especially oligomeric A. Finally, as this project related A to the neuronal death associated
with AD, it is necessary to examine current literature on possible mechanisms of neurotoxicity in
AD.

Genetics of AD
Since the discovery of the first genetic link in AD, multiple genes have been implicated in
AD, with many mutations found to be fully penetrant. The most prevalent FAD mutations occur
on the APP, PSEN1, and PSEN2, all genes associated with production of A (67, 68). One of the
first genes associated with AD was the APP on chromosome 21. Many different mutations have
been identified on the APP most of them leading to FAD (15, 16, 69, 70). Some APP mutations
are neuroprotective, and hypothesized mechanisms of protection include: the lowering of A load,
inhibition of the APP transforming growth factor 2 (TGF2) cell mediated death pathway, or
through the alteration of aggregation kinetics (15, 71).
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Conversely, APP mutations implicated in FAD have been linked to: higher A production,
increased levels of tau, and increases in the A1-42/A1-40 ratio (16, 70). The majority of FAD
mutations are linked to presenilin protein mutations (17). Mutations have been found for both
PSEN1 located on chromosome 14 and PSEN2 located on chromosome 1 (17, 18, 72). PSEN 1
and 2 along with the accessory proteins nicastrin, APH-1, and PEN2 form the -secretase, which
is responsible for the final cleavage of A from the membrane. The prevailing proposed
mechanism of PSEN mutations causing FAD is through partial loss in function of -secretase
activity, leading to only partial processing of A1-42 and increasing the A1-42/A1-40 ratio in the
brain (19, 68, 73).
The previously discussed genes have been linked to FAD, which represents <1% of AD
cases (74). The vast majority of AD cases are SAD, with the strongest known risk factor being
Apolipoprotein E allele (ApoE). ApoE has multiple isoforms with the E2 being neuroprotective
and E4 being a risk factor for AD (74). ApoE aids in the degradation of amyloid beta within
microglial cells, and the ability of astrocytes to clear diffuse A deposits (75-77). Previous studies
have also demonstrated retardation of blood brain barrier (BBB) clearance of amyloid-ApoE
aggregates compared to free A via redirection of clearance from the LRP1 to the VLDLR, which
internalizes A-ApoE complexes more slowly (75). This clearance delay is isoform dependent
with the E4 allele clearing more slowly than E3 and E2. This clearance slowdown may contribute
to buildup of amyloid structures on blood vessels and explain the increased risk of cerebral amyloid
angiopathy (CAA) associated with the E4 allele of ApoE (75).
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Trisomy 21 and AD
Due to the location of the APP gene on chromosome 21, there is a strong correlation
between AD and trisomy 21 or Down syndrome (DS). Two-thirds of full trisomy 21 translocation
patients develop dementia by the age of 60 (78). Interestingly, this association is only present if
the APP gene is present on the extra chromosome, granting a third copy of the gene (79, 80).
Patients without a third copy of APP will have DS without the increased risk of developing AD,
normally associated with it. Furthermore, translocation of a small fragment of chromosome 21
causing duplicate APP copies on a single chromosome cause FAD but not DS (69, 81). The
relationship between an extra copy of APP and AD is strong evidence in support of A as the
causative agent in AD.

The Role of Tau in AD
One of the hallmarks of AD is the presence of intracellular aggregates composed of highly
phosphorylated tau. Tau is a protein involved in the stabilization of microtubules (5). Tau has
multiple phosphorylation sites, and increased phosphorylation levels has an inhibitory effect on
microtubule binding leading to a corresponding increase of soluble tau (82, 83)Phosphorylated tau
has been shown to closely interact with F-actin causing bundling and aggregation of F-actin
forming actin rich rods (84). F-actin is present at the dendritic synapse making tau mediated Factin aggregation a possible mechanism of synaptic loss in AD (85). The presence of NFTs is
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linked to a reduction in expression of synaptic vesicle transport proteins. Levels of soluble tau
correlate with AD implicating soluble tau as the neurotoxic form of tau (83, 86, 87). A has been
shown to cause dendritic spine loss in the absence of tau; however, neuronal death was tau
dependent (88).
Excitotoxicity has been implicated as a mechanism of neuronal death involved in AD (89,
90). Knockout of tau has been shown to attenuate hyper-excitability in mouse models
overexpressing A (91). Strong evidence suggests that tau and A act in concert in AD to cause
synaptic loss and neuronal death (43, 45, 86, 92, 93). However, in the front cortex of AD patients,
A levels were found to be increased prior to the onset of significant tau pathology (94).
Additionally, reduction in soluble A levels has been linked to a decrease in tau accumulation.
Increased levels of A peptides have also been linked to the phosphorylation of tau (82, 93, 95,
96). A dimers isolated from AD brains induce phosphorylation of tau causing neuritic
degeneration (97).This evidence suggests that although a strong link between tau and AD exists,
tau phosphorylation and aggregation is likely a downstream effect of A buildup. This supports
the case that although tau is intimately linked to AD, buildup of A peptide is likely the initiating
factor in AD pathogenesis.
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A Structural Studies
Consistent with the majority of transmembrane proteins, the amyloid beta segment of the
APP is -helical prior to cleavage and exit from the lipid membrane. Supporting this is data from
NMR studies on a segment of the APP containing the A sequence embedded in micelles which
show the A sequence to form an -helix with a disordered C-terminus (98, 99). Structural changes
and aggregation commences once the hydrophobic A peptides enter an aqueous environment.

Amyloid Beta Fibrils
Both solid-state nuclear magnetic resonance (ssNMR) and X-ray diffraction have shown
mature amyloid fibrils to possess a cross -structure; meaning the -sheet plane and backbone
hydrogen bonds connecting -strands are parallel to the main fibril axis while the -strands run
perpendicular to the fibrillar axis (100, 101). Recently, studies have shown the presence of steric
zippers in amyloid fibrils (102, 103). Steric-zippers are formed by the C-terminus of pairs of cross
-sheets with interdigitating side chains (102, 103). TEM studies have shown mature fibrils to
contain one or more protofilaments and to display two-fold symmetry with the fibril cross section
superimposing with itself after 180 degree rotation (104-106).
Studies indicate that amyloid fibrils, formed by both the A1-40 and A1-42, are composed
of in-register parallel -sheets (107-109). However, fibrils formed by the Iowa mutant A peptide
can have either parallel or antiparallel architecture (110). A fibrils and oligomers are polymorphic
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with their internal structure often changing in an environment dependent manner, highlighting the
importance of utilizing relevant experimental conditions (108). Fibrils seeded by brain extracts of
AD patients had different structures, indicating that different seeds can induce formation of distinct
fibrils and that fibril structure is not necessarily consistent between patients (107). A samples
often show intra-sample polymorphism; meaning that measurements such as NMR and CD
demonstrate the average and/or most prevalent of the multiple different structures within a sample
(108). The polymorphic nature of A aggregates complicates the reproducibility of A structural
data.

Oligomeric Amyloid Beta
The toxicity of A oligomers is linked to both oligomer size and structure. Dodecamers of
A isolated from the brains of Tg2576 mice disrupted the memory of young rats (111). While A
dimers isolated from the cerebral cortex of AD brains inhibited LPT in rat hippocampal slices and
impaired memory when injected into rats (112), A dimers, trimers, and tetramers were found to
inhibit LTP in mouse hippocampal neurons at physiological concentrations, with trimers having
the greatest effect (38).Ion mobility, coupled with mass spectroscopy experiments, found that A140

monomers form dimers, which then dimerize, and then likely undergo fibrillogenesis while A1-

42

tetramers went on to form hexamers, and then dodecamers (113).
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It is commonly believed that the toxic species of A are oligomers of mixed -helix/sheet content formed during the transition from -helical monomer to cross -sheet fibril (114116).The transient nature of these aggregates makes their study difficult, therefore structural data
on oligomeric A is lacking. Studies that have been conducted on the oligomeric A have found
presence of both parallel and antiparallel -sheet, along with mixed / structures (117-122). One
group demonstrated that inhibiting the formation of antiparallel -sheet led to a corresponding
decline in toxicity (119). Many studies have used non-physiological conditions in order to stabilize
these oligomers, calling into question the physiological relevance of their findings (49, 66, 115,
116, 123).

A Aggregation
Protein fibrillization is implicated in multiple human diseases including AD, Parkinson’s
disease, and Huntington’s disease. Fibrillization takes place in three stages: a lag phase during
which prefibrillar intermediates are formed, a growth phase of rapid fibril growth and elongation,
and finally growth plateaus once fibrillogenesis reaches equilibrium (124, 125). A fibrillization
takes place via nucleated growth with the C-terminus being critical in the seeding of fibrillization
(126-129). The rate of fibrillogenesis is dependent on both pH and temperature (130, 131). Studies
have indicated that formation of a turn at residues ~23-28 is critical to A fibrillization and toxicity.
This sequence is home to multiple mutations that lead to FAD, indicating the importance of this
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turn to the disease state (132). Structural studies indicate that this turn is part of a -hairpin
structure formed as an intermediate during aggregation (114, 133). Previous studies have found
ApE to aggregate faster than, and have a higher -sheet propensity than A likely due to
increased hydrophobicity (125, 134). Conversely, other studies have found that ApE3-42 aggregates
slower and has lower -sheet propensity (135). Additionally, it was found that ApE3-42 increased
the lag phase of A1-42 and delayed -sheet formation (135). Further studies are needed to clarify
fibrillization kinetics of A1-42 and ApE3-42 as well as the effect ApE3-42 has on A1-42
fibrillogenesis.

Cell Death in AD
There have been many proposed mechanisms of A mediated cytotoxicity. Many different
mechanisms have been demonstrated in vitro, but more study is needed to ascertain their
relationship to the disease in vivo. These mechanisms include the alteration of mitochondrial
dynamics, loss of calcium homeostasis, and trans-nitrosylation of proteins due to increased RNS
production.
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Alteration of Mitochondrial Dynamics
Mitochondrial dynamics, or their constant fission and fusion, is used to dilute
mitochondrial DNA damage and maintain a healthy mitochondria population (136). Alterations in
mitochondrial dynamics has been implicated as a mechanism of both synaptic degradation and
neuronal death in AD. Neurons are highly energy dependent due to the large energy exertion
required to maintain synapses, as well as the re-uptake and release of neurotransmitters. Aged
mitochondria display reduced activity of complex I and IV in the respiration chain (137).
Mitochondrial DNA mutations accumulate over time due to oxidative species formed during
respiration (138). Fractionated mitochondria and broken cristae have been found in AD brains,
indicating a loss of mitochondrial dynamics homeostasis (139). Fragmented mitochondria produce
less ATP production and more reactive oxidative species (ROS) (136). Oxidative damage has been
described in lipid membranes and proteins in AD brains, providing evidence for the role altered
mitochondrial dynamics play in the disease (139, 140). Increases in mitochondrial derived ROS
have been linked to upregulation of APP increasing A levels in a positive feedback mechanism
(141). Increased ROS production is also an early signal of apoptosis (142). Fusion of mitochondria
is carried out via a complex of mitofusins 1 and 2 and optic atrophy 1 (136, 143). Mitochondrial
fission is carried out via dynamin-related protein 1 (drp1), which is targeted to the mitochondrial
outer membrane via: mitochondrial fission factor mitochondrial fission protein 1 and,
mitochondrial elongation factor 1 (136). Up-regulation of mitochondrial fission in AD is believed
to be due to increased activity or localization of drp1 due to post-translational modification,
although the exact mechanism is controversial. Some groups have theorized that this occurs
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through increased GTPase activity of Drp1 via nitrosylation (144, 145). Other groups argue that
the altered dynamics is due to increased targeting of drp1 to mitochondria due to phosphorylation
of drp1 (146). Additionally, enhanced levels of glycogen synthase kinase 3 (GSK3) have been
found in AD patients (96). GSK3 has been linked to phosphorylation of drp1 upregulating its
activity, as well as an increase in Cdk5 activity and tau expression (95, 147).

Loss of Calcium Homeostasis
Loss of intracellular calcium homeostasis is also implicated in AD neuronal death. Calcium
is a vital intracellular signaling molecular responsible for regulating many signal cascades. Loss
of calcium homeostasis has been linked to cellular apoptosis (148). Studies have shown A
peptides to cause deregulation of calcium homeostasis, providing evidence for it being a
mechanism of cellular death in AD (149-155).
There have been many proposed pathways that A affect calcium regulation. A peptides
have been linked to the upregulation of ryanodine receptors, specifically Ryanodine Receptor 3
(RyR3) (153-155). These receptors release calcium from the endoplasmic reticulum (ER) in
response to increases in intracellular calcium termed calcium induced calcium release (CICR).
Increased levels of tau and A are linked to increased glutamate levels through increased
expression and inhibition of re-uptake and transport (156-159). Glutamate can activate both RyR3
and NMDAR increasing intracellular calcium. Soluble A oligomers were found to have high
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affinity for PrPc. These complexes were found to interact with a complex of mGluR5 and Fyn,
causing increased NMDAR activity and thus calcium influx (160). It was also found that these
A-PrPc-mGluR5 complexes mediate dendritic spine loss through eEF2 phosphorylation.
Additionally, A peptides have been shown to inhibit the activity of mGlu7 an NMDAR regulator
further increasing NMDAR activation and subsequence calcium influx. Increases in intracellular
Ca2+ concentrations mediates signaling changes via multiple mechanisms. In response to increased
calcium the calcium dependent protease calpain cleaves the Cyclin dependent kinase 5 (Cdk5)
activators p35 to p25 or p39 to p29, causing aberrant increased Cdk5 activity (161, 162). This
increased Cdk5 activity has been demonstrated to lead to an increase in A production as well as
production and hyper-phosphorylation of tau (95, 161, 162).

Amyloid Pore Formation
Another mechanism of loss of calcium homeostasis in AD is the formation of calcium
permeable channels composed of A in the organelles and plasma membranes of neurons (121,
149, 163-167). These pores have been observed in AD brains and in vitro assays have
demonstrated an influx of calcium through A pores at physiological peptide concentrations,
lending credence to this theory (163, 164, 167). Evidence shows that A behaves similarly to
gramicidin, an antimicrobial agent which has mostly -sheet structure and forms pores in plasma
membranes (168). Additionally, the A oligomer conformation specific antibody A11 binds
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selectively to the bacterial pore forming protein HL as well as human perforin, indicating shared
homology and possibly similar mechanisms of pore formation (169). A close link was found for
both A1-42 and A1-40 between pore formation and cytotoxicity (121). Structural studies indicate
that these pores may consist of -barrel like structures composed of monomers of A in either
parallel or antiparallel -sheet (170, 171). Other MD simulations on short A peptides predict
octameric pores composed of mostly -helical structure (172).

Nitrosylation of Proteins in AD
Excess levels of nitric oxide (NO) leading to increased S-nitrosylation (SNO) of proteins
has been linked to AD (173). NO is produced by nitric oxide synthases (NOS) by the conversion
of L-arginine to L-citrulline, it easily defuses through plasma membranes allowing it to signal
neighboring cells. The two NOS relevant to AD are neuronal nitric oxide synthase (nNOS) and
inducible nitric oxide synthase (iNOS). nNOS is found in neurons and is constitutively active,
producing low levels of NO. iNOS is constitutively inactive, and when activated, produces high
levels of NO. Excessive NMDAR activation in AD has been shown to lead to increased levels of
ROS and NO through nNOS activation (174). Additionally, tangle-bearing neurons in the AD brain
have been shown to have activated iNOS (175). SNO is a post-translational modification wherein
a nitric oxide species undergoes a redox reaction with a thiol group on a cysteine (176). Increasing
SNO of proteins has been linked to multiple neurodegenerative diseases, including AD and
Parkinson’s disease (144, 145, 161, 177, 178). High levels of SNO proteins has a pro apoptotic
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affect (179). Transnitrosylation via S-nitrosylating proteins has been identified as a major
mechanism in the proliferation of SNO proteins throughout cells. Numerous proteins have been
identified as having the ability to transnitrosylate other proteins including GAPDH, Cdk5, and
caspase 3 (176, 180). Cdk5 has been shown to be S-nitrosylated at amino acids 83 and 157 via
interaction with iNOS (181). SNO-Cdk5 can act in several neurotoxic mechanisms, including
Transnitrosylation of drp1, activation of the pro apoptotic protein ATM, and phosphorylation and
loss of function of WAVE1 (180, 182, 183). SNO-Cdk5 has been shown to transnitrosylate Drp1,
enhancing its GTPase activity leading to altered mitochondrial dynamics (144, 145, 180, 181).
SNO-GAPDH has been found in AD brains; SNO-GAPDH binds Siah1 and translocates to the
nucleus where it initiates apoptosis (178, 184, 185). There is also evidence that NO causes cyclin
dependent kinase 1 (Cdk1) mediated phosphorylation of drp1 enhancing GTPase activity and
mitochondrial fission (146).
The nature of AD, namely the long time scale and the difficulty of studying neurons both
in vivo and in vitro, make pin-pointing of a single mechanism of neuronal death difficult. It is
likely that some of the aforementioned mechanisms of cytotoxicity are downstream consequences
of AD and not direct causes; however, it is reasonable to assume that there are multiple often
interconnected neurotoxic pathways in AD. The lack of a single mechanism to target complicates
drug development in AD. A stronger understanding of the relationship between A structure and
toxicity may pave the way the development of early diagnostic tests for AD or novel structure
based AD drugs.
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Methodology Literature Search
The polymorphic nature of the A peptide required detailed review of existing literature.
To ensure that consistent and reproducible results are obtained, it was necessary to use uniform,
monomeric solutions of Ain each experiment. Fluorinated alcohols such as 1,1,1,3,3,3hexafluoro-2-propanol (HFIP) are commonly used to induce -helical structure and
monomerization in A peptides (186, 187). In this work, protein secondary structure was
determined by CD, literature was therefore reviewed in order to interpret CD spectra (188).

Review of FTIR
Due to the importance of FTIR spectroscopy in this work a thorough review of current
literature on FTIR was conducted. Infrared spectroscopy is also called vibrational spectroscopy;
absorption of light is associated with various vibrational modes of chemical groups within a
molecule. Polychromatic infrared radiation is passed through the sample, when the frequency of
infrared radiation matches the vibrational frequency of chemical bonds present in the sample,
absorbance occurs. The absorption frequency of FTIR spectra is displayed in wavenumbers where
wavenumber W=1/=/c; where  is wavelength,  is temporal frequency of vibration, and c is
the speed of light. The vibrational frequency  for a diatomic molecule can be approximated using
equation 1; where the spring constant k is proportional to chemical bond strength.
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There are many vibrational modes that can be observed in FTIR, but the two most relevant
to biological study are the amide I and amide II. The amide I vibrational mode is located 17001600 cm-1 and is primarily generated by C=O stretching vibration. These vibrations are coupled
through covalent bonding, H-bonding, and through space, these couplings shift vibrational
frequency. Protein secondary structure geometry is highly conserved, making the C=O vibrational
frequencies of various secondary structures also highly conserved. This allows accurate attribution
of an FTIR absorbance band to a specific secondary structure. Research was conducted on the
locations of these amide I secondary structure absorbance peaks in order to interpret experimental
results (189-191). The peak wavenumber and extinction coefficient of various protein secondary
structures can be found in chart 1. The amide II is located 1570-1540 cm-1 and is primarily
composed of NH in-plane bending. The amide II can be utilized to measure the solvent
accessibility of the protein. Amide hydrogen-deuterium exchange will take place with the addition
of D2O based buffer. The increased mass of deuterium causes a downshift in absorption and
corresponding loss of absorbance 1570-1540 cm-1. Proteins in more open or solvent accessible
conformations will undergo more H-D exchange and thus lose amide II signal intensity more
quickly than tightly packed proteins.
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C Labeling of Proteins

The
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C-labeling of specific amino acid stretches or entire proteins is a technique to

investigate protein interaction and examine protein secondary structure in a site-specific manner.
The amide I absorbance peaks of peptides 13C-labeled is downshifted thus allowing dissection of
the structure of labeled segments or proteins from unlabeled segments or proteins. This downshift
was reviewed in order to accurately interpret experimental results (192). The downshifted
absorbance of a 13C labeled secondary structure can be accurately predicted as shown in equation
2 by taking the ratio of vibrational frequency of the 13C=16O bond over the 12C=16O and multiplying
the result by the known absorbance of 12C secondary structures shown in table 1 (Equation 2). For
example, by taking the known 12C parallel -sheet absorbance at 1636-1630 cm-1 and multiplying
it by the calculated factor of 0.978, we can predict the absorbance of a 13C parallel -sheet to be
1600-1594 cm-1.
1

1
16
1
+
12 16

√13
1

+

= ~0.978

(2)
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Table 1. Characteristic amide I wavenumber relative extinction coefficients, and integrated absorbance extinction
coefficients (B) of various protein secondary structures in D 2O, integrated extinction coefficient come from (193).

Relative Integrated
Absorbance D2O
Secondary Structure

B
Extinction Coefficient

(cm-1)

-helix

(M-1cm-2)

1655-1638

1

5.1 x107

1636-1630

1.37

7.0x107

1.37

7.0x107

(Weak)

Multiply large
component by 1.07

(7% of Strong
Component)

1625-1613

1.37

7.0x107

-turns

1675-1640

1.08

Unordered Structure

1648-1640

0.88

Parallel -sheet
(Intramolecular)

Anti-Parallel -sheet

1636-1630
(Strong)
1680-1670

Intermolecular (cross) -sheet
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5.5x107
4.5x107

CHAPTER THREE: METHODOLOGY
In this project, we examined A1-42, ApE3-42, and combined samples at both equimolar and
9:1 (A1-42:ApE3-42) ratios. These molar ratios were utilized because ApE has been observed in
AD brains at up to 50% of total soluble A load but is commonly present at a lower ratio (13, 20,
22). However, it has also been demonstrated to have a profound affect even at low molar ratios
(44, 194). The secondary structures of early oligomers and intermediate structures were
determined utilizing FTIR and CD. Peptides were first dissolved at concentrations of either 200 or
50 M in HFIP to break up pre-formed aggregates. Monomer formation of the peptides was
confirmed by the formation of -helix in HFIP (187). The removal of HFIP was conducted by
streaming N2 gas over the samples until dried then vacuum desiccating samples for 15 minutes.
Bulk aqueous buffer was then added to the dried samples. Two different buffers were used
one at near-physiological ionic concentration and one with low ionic content. The nearphysiological buffer was 50 mM phosphate buffer + 50 mM NaCl pH 7.2 (pD 6.8 for FTIR samples
in D2O buffer) and the buffer of low ionic content was 10 mM phosphate pH 7.2 (pD 6.8 for FTIR
samples in D2O buffer). Buffer was added to produce a final peptide concentration of 50 M. The
ApE3-42 is missing 3 N-terminal charges compared to the unmodified A. It is likely these charges
form ionic bonds stabilizing the peptides, increasing ionic pressure will weaken these bonds and
can cause changes in structure distribution. Examining structural changes of the peptides in both
conditions provides information on the structure formed by the N-terminus of the peptide.
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Cytotoxicity Assays
Cytotoxicity assays were conducted with collaboration with Dr. Lucia Cilenti in the
laboratory of Dr. Kenneth Teter. To assay the cytotoxicity of A aggregates, PC12 cells were
grown in RPMI 1640 media, supplemented 10% fetal bovine serum, 50-units/ml penicillin and 50
μg/ml streptomycin. For MTS viability assays cells were seeded in 96-well plates in
triplicate/samples at a density of 10,000 cells/well in 100 μL complete medium for 18 hours.
Following this, 100 μL of fresh medium containing A samples aggregated for 2, 4 and 24 hours
by stirring at 37 °C in PBS, was added to cells followed by incubation at 37 °C for 28 and 50 hours.
Cell viability was determined by MTS assay, a cell proliferation assay, to monitor
methanethiosulfonate tetrazolium reduction as an estimate of cell viability, according to the
manufacturer’s instructions (Promega). In the assay, 20μl of MTS tetrazolium substrate solution
was added to the wells at 28 and 50 hours followed by further incubation at 37 °C for 3 hours, Cell
viability in each well was assayed by reading the absorbance at 590 nm in a BioTek microplate
reader Synergy 2. Percentage of cell viability was calculated by subtracting the average of the
triplicate samples at 490nm absorbance from medium control (no cells/background) from all other
absorbance values.
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Membrane Calcium Release
The ability of A aggregates to induce the release of calcium from lipid vesicles was
assayed using Quin-2. 40 M Quin-2 in the presence of 100 nm unilamellar vesicles of
POPC/POPG/cholesterol (6:3:1) loaded with 30 mM CaCl2 in aqueous buffer pH 7.2. The total
lipid concentration was 0.5 mM and peptides were added for a final ratio 1:100 peptide:lipid.
Peptides were added after 2 and 24 hours of aggregation at 37 oC in PBS. Control was conducted
by addition of PBS followed by complete release of all entrapped Ca2+ via addition of 0.05% Triton
X-100 which disrupted vesicles.

FTIR
All FTIR measurements were taken on a Vector-22 FTIR spectrometer (Bruker Optics,
Billerica, MA, USA) equipped with a liquid N2 cooled Hg-Cd-Te detector with a 2 cm-1 resolution.
All buffers were made utilizing D2O, and not H2O, to avoid artifacts caused by absorption of H2O
in the amide I region. Transmission spectra collected for all samples were taken by co-adding
either 500 or 1000 consecutive scans. Peptides dissolved in HFIP were first deposited on the CaF2
FTIR window, and then desiccated for 15 minutes to remove HFIP. Transmission spectra were
then taken and absorption was calculated using a reference transmission spectra. After the
collection of a dried sample, buffer was added along with a second CaF2 window. Separating CaF2
windows was a 50 m Teflon spacer. Transmission spectra were then taken consecutively and
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absorbance was calculated using a buffer reference. Data for both uniformly and segmentally 13C
labelled peptides was obtained similarly along with data for mixed samples. Samples of
atmospheric vapor was collected separately and used to clean up spectra as necessary. Spectra
were smoothed using a 13-point Savitzky-Golay linear least squares algorithm and then baselined.
Absorbance spectra were prepared using OPUS spectroscopy software.

Curve-Fitting of FTIR Spectra
Curve-fitting of FTIR spectra was performed using GRAMS IO spectroscopy software.
The locations of amide I components were based on negative peaks in the second derivative.
Curve-fitting was considered acceptable when peak wavenumbers of components were in
agreement with the second derivatives, the sum of all components reasonably fit the experimental
spectra, and the peak component widths were within reasonable limits i.e. width at half height of
less than 40 wavenumbers (190). The relative fraction Fi of either -helix (), -sheet (), -turn
(t), and other structures, were calculated based on the area of fit peaks using equation 3 where B
refers to the average integrated extinction coefficient of the described structures as previously
described (195).
𝐹𝑖=

𝑎𝑖
𝑎𝑎 𝑎𝛽 𝑎𝑡 𝑎𝑜𝑡ℎ𝑒𝑟
𝐵𝑖 ( + + +
)
𝐵𝑎 𝐵𝛽 𝐵𝑡 𝐵𝑜𝑡ℎ𝑒𝑟
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(3)

Hydration FTIR
To facilitate examination of early peptide intermediates and structural
transformations peptide transition was delayed by hydrating from gas phase, using D2O vapor and
not aqueous buffer. This was done using two separate mechanisms. In the first, dried peptides both
individually and in combination, were hydrated via exposure to ambient humidity. For the second
a custom apparatus was designed to hydrate peptides inside the FTIR spectrometer via the pumping
in of D2O laden N2 gas (Figure 1). In this setup two separate hoses of N2 gas was bubbled through
two flasks of D2O and then piped into the spectrometer. Peptides were prepared from 50 M stocks
in HFIP as described earlier. To examine the effect of co-incubation peptides were dried on either
the same side or opposite sides of the CaF2 windows to allow comparison between interacting and
non-interacting peptides (Figure 1A).

Figure 2. A) Schematic depiction of the experimental set-up. Nitrogen gas is pumped through simmering D2O into the
sample compartment. Only two of four flasks with D2O are shown for simplicity. Two sample holders are mounted
vertically, at 90 degrees, one with two peptides at opposite sides of a CaF2 window and one with both peptides blended
at one side. Consecutive FTIR spectra of the two samples are measured while the sample holder frame is turned back
and forth by 90 degrees. Red arrows represent the infrared light. B) Photograph of the FTIR spectrometer during an
actual experiment. The inset (middle bottom) provides a glimpse into the sample compartment.
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Circular Dichroism
CD measurements of A in HFIP were taken in either a 0.5 mm cylindrical cuvette or a
4x4 mm rectangular quartz cuvette. Measurements were conducted on a Jasco J-810
spectropolarimeter (Tokyo, Japan). For measurements in aqueous buffer HFIP was removed with
N2 gas followed by desiccation for 30 minutes, prior to the addition of buffer. After the addition
of 50 mM phosphate + 50 mM NaCl pH 7.2 aqueous buffer samples were incubated at 37oC while
stirring and a final protein concentration of 50 M. CD measurements were taken between 330180 nm. After collection spectra were smoothed in Spectra Manager software using 9 point
Savitzky-Golay linear least squares algorithm.

TEM
TEM measurements were performed with the assistance of the lab of Dr. Bo Chen
(University of Central Florida, Orlando, FL, USA). Peptides were dissolved in HFIP, dried, and
buffer was added as previously described. Samples were then stirred at 37oC for 24 hours. For
measurements 5 mL of sample was placed on graphene coated grids. After five minutes excess
buffer was removed. Samples were then washed twice with diH2O and negatively stained with 3%
uranyl acetate. Samples were measured on a JEOL TEM-1011 (Tokyo, Japan) at 80kV. Samples
were examined at 2,4,12, and 24 hours to examine aggregation and morphology.
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CHAPTER FOUR: RESULTS

Pyroglutamylated Amyloid- Peptide Reverses Cross -Sheets by a Prion-Like Mechanism

Circular Dichroism of A Proteins
We first sought to clear up disagreement in the literature about the -sheet propensity of
ApE compared to the unmodified peptide. Some groups reported ApE to have a lower -sheet
propensity than the unmodified peptide while others have proposed the opposite. To clear up this
contradiction we examined the structural changes of ApE and unmodified A throughout
aggregation using CD.
To prepare monomeric samples A was first dissolved in HFIP to break up pre-formed
aggregates. HFIP disrupts -sheet formation and promotes formation of -helical structure (187).
CD spectra of peptides dissolved in HFIP at 50 M show a minima at 203 with a shoulder at 220
nm (Figure 3A). This is indicative of -helix and disordered structures. This is in agreement with
previous data of A proteins in HFIP and implies a monomeric solution. Spectra taken after the
removal of HFIP indicate that the peptides are -helical shown by two minima located at 208-209
nm and 221-224 nm (Figure 3B). Interestingly, the ApE3-42 has a significantly reduced 208/222
ratio, indicating a more flexible or disordered -helix (196).
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Figure 3. (A) CD spectra of A1-42 (red), ApE3-42 (blue) their 9:1 (teal) and, equimolar (green) ratios in HFIP at a
peptide concentration of 50 M. (B) CD spectra of the same peptides following HFIP removal via N 2 drying and
vacuum desiccation.

Following desiccation aqueous buffer was added to the sample for a final peptide
concentration of 50 M and samples were constantly stirred at 37°C. In physiological buffer
conditions A1-42 rapidly forms -sheet as shown by the broad minima at 216-219 nm present 10
minutes after the addition of buffer (Figure 4A). After 16 hours this minima had red shifted to 220
nm possibly indicating decreased accessibility of the solvent due to tight packing during
aggregation, such as in fibrillogenesis. Alternatively, ApE3-42 spectra at 10 minutes has a wide
minima from 208-230 nm likely indicating presence of -helical, -sheet, and turn structures
(Figure 4B). After 2 hours this minima has shrunk to 212-223 nm indicating the presence of a
combination of both -helical and -sheet structures. After 24 hours of aggregation a single
minima at 219 nm is present indicating a majority -sheet structure. This demonstrates that A1-42
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readily forms -sheets while ApE3-42 has a higher propensity to retain -helical structure and
delayed formation of -sheet.
The 9:1 (A1-42:ApE3-42) combination after 10 minutes of aggregation contains a wide
minima at 217 nm consistent with the presence of mostly -sheet (Figure 4C). Throughout
aggregation this peak grows in intensity, after 24 hours a single minima at 219 nm is present
indicating the likely presence of fibrils. For the first hour the equimolar combination contains
mixed -helix/-sheet content indicated by the wide minima 210-216 at ten minutes and two
minima at 212 and 222 nm after one hour (188). At 2 hours of aggregation onward a minima
located at 217 nm indicates presence of mostly -sheet structure. The equimolar combination after
one hour resembles the ApE3-42 in that it retains -helical structure and resists converting fully to
-sheet structure (Figure 4D).
This data indicates that ApE has a lower -sheet propensity than unmodified A. Data
from combined samples indicates that ApE3-42 alters A1-42 structural transition. Alone, A1-42
rapidly forms fully -sheet aggregates, while forming mixed -helix/-sheet aggregates in
equimolar combination with ApE3-42.
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Figure 4. CD spectra of A1-42 (A), ApE3-42 (B), their 9:1 (A 1-42/ApE3-42) (C) and, equimolar (D) ratios in 50 mM
phosphate 50 mM NaCl buffer pH 7.2 Spectra are shown 10 minutes (red), 1 hour (green), 2 hours (blue) and, 24
hours (pink) after addition of buffer. Final peptide concentration was 50 M and aggregation took place at 370C with
constant stirring. For A1-42 the spectra in pink corresponds to 17h as subsequent time points gave weak signal due to
evaporation of the sample. Spectra were cut at 210 nm due to weak signal from Cl and peptide absorbance.

TEM of A Fibrils
Secondary structure is linked to fibrillogenesis and fibril morphology (134). The structural
differences between the two peptides therefore indicate a strong possibility of altered
fibrillogenesis. There are currently disagreements in the literature about the fibrillization kinetics
of ApE in comparison to the unmodified peptides. To clear this up, fibril formation and
morphology was examined via TEM. Samples were examined at 2,4,12, and 24 hours of
aggregation in 50 mM phosphate + 50 mM NaCl buffer pH 7.2. To determine the effect of peptide
interaction peptides were examined separately as well as in equimolar and 9:1 (A1-42:ApE3-42)
mixed samples.
The largest differences between samples was observed after 2 hours of incubation. The
ApE3-42 sample is dominated by irregularly shaped prefibrillar aggregates with dimensions
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between 30-100 nm (Figure 5b). The A1-42 sample at 2 hours consists mostly of fibrils with a
smaller number of pre fibrillar aggregates (Figure 5a). The rapid formation of pre-fibrillar
aggregates by ApE3-42 may be due to its increased hydrophobicity. Both the 9:1 (Figure 5c) and
1:1 (Figure 5d) samples resemble the ApE3-42 sample with a large number of pre-fibrillar
aggregates compared to mature fibrils. At 4 hours fibrils were present in all samples along with
significant amounts of prefibrillar aggregates (Figure 5e-h). At 12 (Figure 5i-l) and 24 (Figure 5mp) hours fibrillogenesis continued and more mature fibrils were found in all samples along with
decreased levels of prefibrillar aggregates.
This data demonstrates that the unmodified A undergoes more rapid fibrillogenesis than
ApE. This data agrees with CD data showing that A1-42 rapidly forms -sheet indicative of fibril
formation while ApE3-42 and the 1:1 combination retain a prominent -helical component. The
increased levels of prefibrillar aggregates compared to fibrils at two hours in mixed samples
demonstrates that ApE3-42 has a profound effect on fibrillogenesis particularly in the early stages
of aggregation (135). The lack of fibrils in the 9:1 sample is evidence of the strong effect ApE3-42
can exert even at low molar ratios. Interestingly, in the 9:1 sample there was no delay in -sheet
formation coinciding with the delay in fibrillogenesis. This indicates that the delay in
fibrillogenesis found in mixed samples may not simply be due to inhibition of -sheet formation.
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Figure 5. TEM images of Aβ1−42 (a, e, i, m), AβpE3-42 (b, f, j, n), AβpE3-42/Aβ1−42 = 1:9 (c, g, k, o), and AβpE3-42/Aβ1−42 =
1:1 (d, h, l, p) incubated in aqueous buffer of 50 mM NaCl + 50 mM Na,K-phosphate (pH 7.2) for 2 h (a−d), 4 h (e−h),
12 h (i−l), and 24 h (m−p) at 37 °C with constant stirring. The horizontal bar in each panel equals 100 nm.

FTIR of Amyloid Beta Peptides
We next sought to examine the structure of these peptides in greater detail utilizing FTIR.
FTIR gives greater structural resolution than CD allowing, for instance, the determination of
whether the protein is forming intramolecular or intermolecular -sheet. Formation of
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intramolecular -sheet and not intermolecular -sheet, as found in fibrils, may explain the delay
of fibrillogenesis despite rapid -sheet conversion of the 9:1 sample. Utilizing uniformly

13

C-

labeled A1-42 allowing the assignment of structural components to individual peptides in mixed
samples. This allowed the probing of structural changes in both peptides caused by interaction
with one another.
Peptides were first examined individually by depositing 40 L of a 200 M solution of A
in HFIP to the CaF2 FTIR window. HFIP was then removed via vacuum desiccation for 15 minutes
and FTIR measurements were taken of the proteins in a dried state. The 13CA1-42 spectra contains
a major peak at 1588 cm-1 indicating the presence of intermolecular -sheet structure (Figure 6).
It also contains a broad component likely corresponding to -turns (~1660 cm-1) and an
insignificant -helical component (1617 cm-1). The ApE3-42 is forming intramolecular -sheet that
is possibly anti-parallel as indicated by the peak at 1634 cm-1 and small shelf present at 1695 cm1

(189) (Figure 6). The presence of structures other than -helix in the dry samples indicates that

the peptides can undergo structural transitions in the absence of aqueous buffer due to atmospheric
humidity.
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Figure 6. FTIR spectra of AβpE3-42 (Light Blue) and uniformly 13Clabeled Aβ1−42 (Green) dried from a 200 μM HFIP
solution on a CaF2 Window. The amide I area of spectra was normalized.

The observation that atmospheric humidity was sufficient to induce structural changes gave
us the idea to examine the effect of ApE3-42 on the early stages of A1-42 aggregation utilizing
atmospheric humidity. Using humidity we examined early transitions of both equimolar and 9:1
molar combination samples. Samples in HFIP were added to FTIR windows and HFIP was
removed by desiccation as described earlier. Samples were then exposed to atmospheric humidity
for either 10 or 20 minutes and FTIR spectra was taken. Individual peptides were also measured
after 15 minutes of atmospheric humidification and their weighted sum was compared to combined
samples. The absorption of atmospheric humidity is demonstrated by a corresponding increase in
absorbance in the H2O band located 3450-3150 cm-1 (Figure 7A). In the 9:1 molar ratio, as the
sample is hydrated the structure transitions from -helix (1617 cm-1) to -sheet (1592 cm-1)
evidenced by an increased 1592/1617 ratio in the 20 minute sample when compared to the 10
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minute sample (Figure 7B). The broad peak ~1655 cm-1 likely corresponds to A1-42 turn structure
as well as ApE3-42 turn and -helical structures. The lower absorbance by the weighted sum of
individual peptides at 1617 cm-1 indicates less -helical content in the A1-42 in the absence of
ApE3-42. This is evidence that ApE3-42 restricts -helix to -sheet transition of the A1-42. The
differences in the equimolar samples are even more pronounced. The weighted sum at 15 minutes
contains prominent peaks at 1588 and 1634 cm-1 likely corresponding to intermolecular -sheet of
the A1-42 and intramolecular -sheet of the ApE3-42 respectively (Figure 7C). The broad shelf
~1660 cm-1 is likely composed of A1-42 turns as well as ApE3-42 -helix and turn structures.
Experimental spectra at 10 minutes show a decrease in -helix-to--sheet transition of ApE3-42
evidenced by a decrease in 1634/1658 ratio when compared to the weighted sum. The A1-42 helix-to--sheet transition is also inhibited at 10 minutes as demonstrated by an increase in peak
height at 1617 cm-1 and a decrease in the corresponding -sheet height present at 1595 cm-1 in the
experimental and 1588 cm-1 in weighted sum spectra’s respectively. The peak at 1595 cm-1 likely
corresponds to intra- not intermolecular -sheet structure. At 20 minutes the differences are even
more pronounced. The major peak at 1658 cm-1 indicates that ApE3-42 is mostly -helical. Minor
shelves located at 1617 and 1595 cm-1 correspond to A1-42 -helix and intramolecular-sheet
respectively. The similar intensities at 1617 cm-1 for both 10 and 20 minutes indicate a lack of
transition from -helix of the A1-42.
This data indicates that at 10% of total peptide ApE3-42 delays formation of cross-
structure of A1-42. At 50% the effect is even more pronounced with Ape3-42 inhibiting
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intermolecular -sheet formation of A1-42 in favor of intramolecular at 10 minutes, and inhibiting
any -sheet formation at 20 minutes. Additionally, the ApE3-42 forms more -helix than -sheet
when in combination with A1-42, this indicates that A1-42 inhibits ApE3-42 -to- conversion.

Figure 7. FTIR spectra of AβpE3-42 and uniformly 13CAβ1−42 at 1:9 molar ratio (A and B) and 1:1 molar ratio (C). Green
and Red lines are experimental spectra of a sample prepared in HFIP, followed by solvent removal by desiccation and
exposure to atmosphere for 10 and 20 min, respectively. The Blue is the weighted sum of the spectra of each peptide
measured individually, exposed to the atmosphere for 15 min. Construction of the weighted sum spectra is described
under Figure 4. Panel B is a zoom-in into the amide I/II region of spectra shown in panel A.

We next examined structural differences between the peptides in aqueous buffer, 10 mM
phosphate pD 6.8 buffer was added to samples following measurement of the dried peptides and
spectra were taken every ten minutes. After the addition of buffer both peptides formed
predominantly intermolecular -sheet structure evidenced by a major peak at 1628 cm-1 for the
ApE3-42 (Figure 8B)and 1585 cm-1 for the 13CA1-42 (Figure 8A). Additionally, the ApE3-42 had
significant turn and -helical components as evidenced by the secondary peak ~1673 cm-1. The
small peak at 1673 cm-1 in the 13CA1-42 sample is likely due to trifluoroacetic acid (TFA) which
is commonly found in synthesized peptides.
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Examination of the Amide II components of spectra gives additional insight into protein
structure. Use of a D2O based buffer causes hydrogen-deuterium (H-D) exchange and a
corresponding loss of amide II intensity around 1540 cm-1(190, 197). Examination of the Amide
II of both peptides for two hours shows a loss of amide II intensity for the ApE3-42 and no loss of
intensity for A1-42 (Figure 8). The lack of a drop in Amide II intensity indicates that the amide
hydrogens are being shielded from the buffer via formation of a more compact tertiary structure
and/or a less flexible secondary structure, as is found in mature fibrils.

Figure 8. FTIR spectra of A1-42 (A) and ApE3-42 (B) in 10 mM Na,K-phosphate in D2O, pD 7.2. Change from Blue
to Red corresponds to time of exposure of the peptides to the buffer for 10, 30, 50, 70, 90, and 120 min.

Next, we examined spectra of mixed 13CA1-42 and ApE3-42 samples to determine structural
effects of co-incubation. After 2 hours of incubation in 10 mM phosphate pD 6.8 experimental
spectra were compared to the weighted sum of individual spectra. When compared to the weighted
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sums of individual spectra the A1-42 -sheet peak (1585 cm-1) is upshifted by 3 and 10 cm-1 in the
9:1 (Figure 9A) and 1:1 samples (Figure 9B) respectively. The latter shift to 1595 cm -1 implies
formation of intra- not inter-molecular -sheet. The ApE3-42 -sheet peak (1626-1628 cm-1) was
downshifted compared to individual peptides by 4 cm-1 in the equimolar combination. These shifts
are likely due to

13

C:12C coupling and imply strong interactions between the two peptides. It is

thus clear that A1-42 and ApE3-42 form hybrid oligomers composed mostly of -sheets. Curiously,
in the 9:1 sample ApE3-42 is upshifted 10 cm-1 from 1626 to 1636 cm-1 (Figure 4A). This peak can
most likely be attributed to intramolecular not intermolecular -sheet which is characteristic of
mature fibrils. This implies that when incubated with A1-42 at low molar ratio ApE3-42
fibrillogenesis may be inhibited.

Figure 9. FTIR spectra of AβpE3-42 and 13CAβ1−42 combined at 1:9 (A) and 1:1 (B) molar ratios, incubated in a D2Obased phosphate buffer (pD 7.2) for 2 h, at a total peptide concentration of 100 μM. Red and Blue lines are the
experimental spectra obtained on the two peptides combined in one sample and the weighted sums of individual
spectra, respectively. The weighted sums were obtained as A = Σf iAi, where fi is the molar fraction and Ai is the
absorbance spectrum of each individual peptide measured separately.
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This project gave insight into the structural transitions of A1-42 and ApE3-42 as well as the
structure of early oligomers. It was found that A1-42 has a greater -sheet forming propensity than
ApE3-42. Additionally, in hybrid samples ApE3-42 delays or even reverses formation of cross sheet by A1-42. The effect of ApE on fibrillogenesis was demonstrated via TEM data showing
mature fibrils in the A1-42 samples while the ApE3-42 sample contains mostly prefibrillar
aggregates. The hybrid samples resemble the ApE3-42 indicating a strong effect on fibrillogenesis.
FTIR data indicates that ApE inhibits formation of A1-42 intermolecular -sheet which makes
up fibrils. This inhibition of -sheet formation and thus fibrillization of A1-42 by ApE3-42 is
interesting and a possible mechanism of increased toxicity. Delay or inhibition of fibrillization
likely leads to a corresponding increase in the population of soluble oligomers or drive the
formation of off-pathway aggregates of increased toxicity. However, the lack of -helical structure
in FTIR of dried peptides indicates structural transitions had occurred before buffer addition,
calling these results into question. In addition the peptides were examined in buffer with
significantly less ionic content that in physiological conditions. Moving forward with this project,
we sought to examine the early oligomer structure of ApE and unmodified A as well as address
these two concerns.
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Isotope-Edited FTIR Reveals Distinct Structural Features of Unmodified and Pyroglutamylated
Amyloid- Peptides During oligomerization
Next, we sought to characterize the structure of oligomers formed by A1-42 and ApE3-42
as well as hybrid oligomers (198). In mixed samples it was observed that ApE3-42 inhibits cross sheet formation and fibrillogenesis of A1-42. A oligomers are heavily implicated in AD but little
is known of their structures, so we wished to better characterize the structure of the oligomers
formed by these peptides. Here we utilized peptides

13

C- and

15

N-labeled at specific stretches,

these labels allow site specific determination of secondary structure as well as provide tertiary and
quaternary structural information. Labeled proteins were examined in both 10 mM phosphate
buffer pD 6.8 as well as in near-physiological 50 mM phosphate + 50 mM NaCl buffer pD 6.8.
These data provide structural constraints for the modeling of early monomers and oligomers of
A. Using these constraints, we propose a possible structure for monomeric A as well as likely
mechanisms of early oligomerization.

Isotope Labeling of Peptides
In order to gain site-specific secondary structural information we utilized peptides that had
been

13

C and

15

N labelled at specific locations. Peptides were generated with labels in two

locations, K16L17V18 and V36G37G38V39. Solution NMR studies of the A containing APP segment
reconstituted in micelles show an -helix starting at K16L17V18 and a bend involving V36G37G38V39
near the C-terminus. After cleavage of A from the membrane this -helical structure undergoes
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structural transitions eventually forming the cross -sheet structure found in fibrils. The

13

C

labelling of these segments causes a downshift in the amide I spectra allowing site-specific
secondary structural information. In addition by examining the carbon coupling of these labelled
segments we are able to gain quaternary structural information. If two labelled segments are in
close proximity as is found in the in-register parallel -sheet characteristic of fibrils they will
undergo

13

C:13C coupling and a further downshift of absorbance will occur. If the labelled

segments are not in close proximity to one another they will instead undergo 13C:12C coupling and
a slight upshift of their associated absorbance peak will occur.

FTIR of Dried Proteins
Prior to the addition of buffer, measurements were taken of the peptides dried from HFIP.
Peptides in HFIP were first deposited on the CaF2 window and then HFIP was removed via
desiccation. It was previously observed that atmospheric humidity is sufficient to induce structural
changes. In order to obtain reliable data, HFIP is used break up pre-formed aggregates and
monomerize A. Previously, in CD of proteins dried from HFIP we observed -helical structures.
We sought to capture this -helical structure in FTIR to ensure consistent A populations prior to
the addition of bulk aqueous buffer. To ensure this, we lowered the protein concentration to 50
M in HFIP, as high concentrations have been shown to induce aggregation (199). When peptides
were dried from HFIP, using the lower concentration and keeping care not to keep samples in the

46

humid lab air for long, both ApE3-42 and A1-42 as well as their equimolar combination form mostly
-helical structure, evidenced by the absorption peak at 1658-1662 cm-1 (Figure 10A). This
absorbance is higher than is found in more stable -helices (1647-1657 cm-1) and suggests that the
-helix formed by A peptides is more flexible. This more flexible -helix agrees with previous
data of the A1-42 segment of the APP (98, 99). To accurately place and quantify the additional
peak generated by the labeled residues the second derivative of dried spectra was calculated
(Figure 10B). Peak fitting was then performed to quantify the additional peaks (Table 2) (Appendix
A). For K16L17V18 labeled peptides an additional peak at 1624-1628 cm-1 is found corresponding
to the labelled segment. This area is consistent with -helix composed of 1-4 13C labeled residues
(190). The reason for the less-than-expected downshift is i-i+4 H-bonding with unlabeled peptides.
In peptides labeled at V36G37G38V39 the dried spectra contains an additional peak at 1596-1602
cm-1. This peak is located at a lower wavenumber and is lower intensity than would be expected
from a

13

C -helix comprising 4/42 or 4/40 suggesting that the C-terminus of the protein is

disordered and the peptides are acting as isolated oscillators (Table 2) (190). This data indicates
that in a dry state the peptides adopt a flexible -helical structure involving K16L17V18 while the
V36G37G38V39 sequence close to the C-terminus is unordered. This agrees with previous
observations of A containing segments of the APP reconstituted in micelles as well as MD
simulations (98, 99, 200). This demonstrates that these dried peptides resemble A prior to
membrane release into an aqueous environment, making them a biologically relevant starting
material for the study of A structural changes and aggregation.
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Figure 10. (A) FTIR spectra of dry peptides in the amide I regions. Spectra for unlabeled and isotopically labeled A142 and A pE3-42 peptides and their 1:1 combinations are presented. Gray dotted lines correspond to A pE3-42, and solid
black lines correspond either to Ab1-42 or to combined samples, as indicated. KLV or VGGV imply the peptides have
been labeled at K16L17V18 or V36G37G38V39, respectively. In KLV/VGGV or VGGV/KLV samples, the first stretch
applies to Aβ1-42 and the second to AβpE3-42. (B) Second derivatives of the corresponding FTIR spectra.
Table 2. Relative amide I content of the 13C labeled peaks in peptides dried from HFIP. In the columns with two
different labels the first one corresponds to A1-42 and the second to ApE3-42.
A1-42

ApE3-42

1 to 1

KLV/VGGV

VGGV/KLV

Total

KLV

12.3%

15.5%

13.3%

13.0%

12.6%

13.3±1.3%

VGGV

8.2%

12.4%

8.9%

2.2%

7.4%

7.8±3.7%
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FTIR of Unlabeled Peptides
After measurement of dried peptides aqueous buffer was added and measurements were
taken consecutively (1000 scans takes ~10 minutes). After 10 minutes in 10 mM Phosphate buffer
pD 6.8 the peptides and their equimolar combination form type 1 -turn and intramolecular sheet as evidenced by the major peaks at 1673 and 1635-1630 cm-1 respectively (Figure 11D)
(190). Consistent with previous observations, the peptides retain some -helical structure
evidenced by absorption ~1660 cm-1. Peptides in near-physiological buffer conditions have similar
absorption peaks and shape indicating formation of type 1 -turn, -helix, and intramolecular sheet (Figure 11A). After 2 hours the location of the -sheet was downshifted 2-5 cm-1 likely due
to H-D exchange. This indicates that the peptides are in a loose conformation allowing solvent
access to the majority of peptides residues (Figure 11C). The -sheet absorbs 1633-1628 cm-1
indicating the presence of intramolecular -sheet as intermolecular -sheets absorb at a lower
wavenumber 1613-1625 cm-1. In near physiological conditions ApE3-42 contains more -helix and
less -sheet compared to A1-42 indicated by a higher ratio 1660/1630-35 cm-1(Figure 11A-C). In
low ionic buffer conditions the opposite is true with A1-42 containing more -helix and less sheet than ApE3-42 (Figure 11D-F). These differences are evident when examining A1-42 –ApE342

difference spectra. In physiological ionic conditions a negative peak at 1660 cm-1 and a positive

peak at 1620 cm-1 indicate more -helix and less -sheet in the ApE3-42 sample compared to the
A1-42 (Figure 12A). The opposite is seen in low salt buffer with a large negative peak at 1620 cm1

and a positive peak at 1660 indicating less -helix and more -sheet in the ApE3-42 (Figure 12C).
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Taking the difference spectra of the 1:1 and the weighted sums of the individual peptides show
differences caused by peptide interactions. If there were no changes due to peptide interaction this
line would be flat. In physiological ionic conditions difference spectra has positive components at
1670 and 1653 cm-1 and a negative component at 1625 cm-1, indicating peptide interaction
enhances formation of -turn and -helix and inhibits -sheet formation (Figure 12B). In low salt
a positive component at 1673 cm-1 and a negative one at 1625 cm-1 are present (Figure 12D). This
indicates that peptide interaction causes formation of more -turn and less -sheet structure. In
near-physiological conditions the 1:1 sample more closely resembles the ApE3-42 forming more
-helix and less -sheet; this agrees with previous data that ApE3-42 strongly influences the
structure of hybrid samples. In low salt conditions the 1:1 more closely resembles the A1-42
forming more -turn and less -sheet structure.
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Figure 11. FTIR spectra of 50 mM A1-42 (Green) ApE3-42 (blue) and their equimolar combination (Red) in 50 mM
phosphate + 50 mM NaCl pD 7.2 (ABC) and in 10 mM phosphate pD 6.8 (DEF) buffers. Time points shown are 10
minutes (A,D) 60 minutes (B,E) and 120 minutes (C,F). Total peptide concentration is 50 M
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Figure 12. Difference FTIR spectra of Aβ1-42 and AβpE3-42 peptides and their equimolar combinations in 50 mM NaCl
+ 50 mM phosphate buffer (A, B) and 10 mM phosphate buffer (C, D), pD Spectra in A) and C) show the difference
Aβ1-42 - AβpE3-42, and those in B) and D) show the difference between 1:1 combination and the normalized sum of the
spectra of the two peptides. Blue, green, and red correspond to the peptide samples incubated in a D 2O-based buffer
for 10, 60 and 120 min, respectively. Total peptide concentration is 50 μM.

In order to quantitate the relative fractions of secondary structure present peak fitting was
performed with peaks being placed based on the second derivative of the spectra (Appendix B).
While peak fitting it was noticed that in 50 mM phosphate + 50 mM NaCl pD 6.8 buffer the 1:1
-helix was downshifted to ~1653 cm-1. This downshift is likely due to helix stabilization. Peaks
were assigned to secondary structures based on location of the absorbance peak. Data after 10, 60,
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and 120 minutes of hydration was averaged (Table 3). In physiological buffer conditions ApE3-42
contains more -helix and less -sheet than A1-42 while the opposite is true in buffer of less ionic
content. The 1:1 combination similarly resists -helix-to--sheet conversion.
This is consistent with our previous observations that ApE3-42 is able to retard -sheet
formation in hybrid samples. The changing -helical propensity based on ionic conditions is
evidence that the -helix is located in the N-terminus of the peptides. The -helix of A1-42 can be
stabilized by ionic interactions at the N-terminus such as D1-K16, E3-K16, D1-R5, R5-E11. Higher
concentrations of ionic charges will weaken this ionic stabilization. The ApE3-42 is missing three
N-terminal charges and thus does not form some of these stabilizing ionic interactions.
Table 3. Secondary structures of A1-42, ApE3-42, and their equimolar combination in 50 mM phosphate 50 mM NaCl
pD 6.8 (light blue) and 10 mM phosphate pD 6.8 (unshaded) determined by curve fitting of amide 1 spectra. Numbers
shown are averages taken after 10, 60, and 120 minutes in buffer. Other refers to all other peaks fit and is primarily
composed of unordered structure.

-helix

-sheet

-turn

A1-42

ApE3-42

1 to 1

11.0±2.4

18.7±3.2

22.9±3.6

24.8±5.1

13.6±1.8

16.3±2.1

50.4±4.6

43.0±4.4

34.5±3.9

38.7±4.8

48.9±3.6

34.2±3.2

18.1±3.3

20.3±1.7

28.4±2.4

24.0±2.7

19.8±1.3

27.7±3.6

20.5±3.9

18.0±2.2

14.2±1.3

12.5±3.6

17.7±2.6

21.8±2.7

other
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FTIR of Labeled Peptides
After dry measurement of the labeled peptides buffer was applied and consecutive
measurements were taken as with the unlabeled peptides. After ten minutes in both buffers the
spectra for the peptide resembles the unlabeled with major peaks ~1673 cm-1 and between 16371628 cm-1 corresponding to type 1 -turn and intramolecular -sheet respectively (Figure 12).
Overlaying the K16L17V18 and V36G37G38V39 spectra over the unlabeled spectra discussed
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previously identifies an additional peak located ~1598-1604 cm-1(Figure 13). This peak can be
attributed to the 13C labeled amino acids in the peptides.

Figure 13. FTIR spectra of A1-42 (A,D), ApE3-42 (B,E) and, their 1:1 combination (C,F) after 10 minutes in 50 mM
phosphate 50 mM NaCl pD 7.2 (A,B,C) and 10 mM phosphate pD 7.2 (D,E,F) buffers. Colors correspond to unlabeled
peptide (Red) as well as proteins 13C- and 15N- labeled at K16L17V18 (Blue) and V36G37G38V39 (green). Total peptide
concentration is 50 M.

When labeled at K16L17V18 in 50 mM phosphate + 50 mM NaCl pD 6.8 buffer the ApE342

retains more -helix than A1-42 as with the unlabeled peptides (Figure 14 A-C). The A1-42

instead forms more type 1 -turn structure demonstrated by the larger absorbance at 1673 cm-1.
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Additionally, the -sheet absorbance of the A1-42 is downshifted 3-5 wavenumbers in comparison
to the ApE3-42 indicating faster formation of -sheet compared to the ApE3-42. The 1:1
combination -sheet peak absorbs ~1633cm-1 between A1-42 and ApE3-42. This agrees with our
previous observations that ApE3-42 has lower -sheet propensity than A1-42 and could retard sheet formation of the A1-42 in hybrid samples. When labeled at V36G37G38V39 the ApE3-42
contained more -turn and less -sheet structure than A1-42 indicated by peak heights at 1673 and
~1635 cm-1 respectively (Figure 14 D-F). As with the K16L17V18 labeled proteins the -sheet peak
of A1-42 is at lower frequencies than ApE3-42 indicating faster -sheet formation.
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Figure 14. FTIR spectra of A1-42 (green), ApE3-42 (blue) and, their equimolar (red) combinations after 10 (A,D) 60
(B,E) and, 120 (C,F) minutes in 50 mM phosphate 50 mM NaCl pD 7.2 buffer. Peptides are 13C- and 15N-labeled at
K16L17V18 (A,B,C) and V36G37G38V39 (D,E,F). Total peptide concentration is 50 M.

When 10 mM phosphate pD 6.8 buffer was added to the peptides the A1-42 formed a higher
fraction of -turn structure indicated by the peak at 1673cm-1 (Figure 15). Additionally, in the
K16L17V18 labeled peptides the -sheet peak wavenumber of the ApE3-42 is shifted several
wavenumbers lower than A1-42 indicating faster -sheet formation by the ApE3-42 (Figure 15AC). The 1:1 -sheet is again located between the A1-42 and ApE3-42 -sheet wavenumbers
indicating that A1-42 retards -sheet formation in the hybrid sample. This agrees with our previous
data that ApE3-42 has a lower -sheet propensity than the A1-42 and can delay -sheet formation
in hybrid samples in physiological buffer conditions while the opposite is true in buffer of low
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ionic

content

Figure 15. FTIR spectra of A1-42 (green), ApE3-42 (blue) and, their equimolar (red) combinations after 10 (A,D) 60
(B,E) and, 120 (C,F) minutes in 10 mM phosphate pD 7.2 buffer. Peptides are 13C- and 15N-labeled at K16L17V18
(A,B,C) and V36G37G38V39 (D,E,F). Total peptide concentration is 50 M.

To facilitate placement of the labeled peak the second derivative was calculated,
examination of the second derivative show a peak that can be assigned to the labeled segment
~1603-1598 cm-1 (Figure 16). To further quantify this peak as well as to examine secondary
structure distribution peak fitting was conducted for spectra taken 10, 60, and 120 minutes after
buffer addition (Appendix C). Taking into account our observed intramolecular -sheet peaks of
1637-1628 cm-1 we can predict 13C-labeled -sheets to absorb 1601-1592 cm-1 therefore we can
reliably say that the labeled segment is forming intramolecular -sheet. As discussed earlier, in
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samples containing both

13

C- and12C-labeled samples the

vibrational coupling with either

13

13

C-labeled residues can undergo

C or 12C-labeled residues depending on whichever is in close

proximity. This coupling changes vibrational frequency with 13C:13C coupling causing a downshift
and

13

C:12C coupling causing an upshift in absorbance wavenumber. Taken with our previous

calculation we can reasonably assign an absorbance 1603-1599 to 13C-labeled -sheets undergoing
13

C:12C-coupling and the absorbance 1596-1592 to

C-labeled -sheets undergoing

13

13

C:13C-

coupling. Therefore, based on the location of the labeled peak in the second derivative we can
reasonably conclude that in these samples in any combination neither K16L17V18 nor V36G37G38V39
segments are adjacent to themselves or one another.

Figure 16. Second derivative of FTIR spectra taken 10 minutes after the addition of A) 50 mM phosphate + 50 mM
NaCl pD 6.8 and B) 10 mM Phosphate buffer pD 6.8. For spectra labeled KLV/VGGV or VGGV/KLV the first
corresponds to A1-42 and the second to ApE3-42.
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A Modeling
Although FTIR data generally does not give tertiary or quaternary structural information
site-specific 13C-labeling gave site-specific structural information. This information along with the
other data collected here gives structural constraints useful in the modeling of early A oligomers
and oligomerization. First, in aqueous buffer both A1-42 and ApE3-42 forms a mixture of primarily
intramolecular--sheet with lesser amounts of, -helix, -turn, and unordered structures. This helix can be placed at the N-terminus based on data collected in buffers with two different ionic
contents indicating that ApE3-42 has a higher -helix propensity than A1-42 in physiological
conditions while the opposite is true in buffer with low ionic content. Second, the segments
K16L17V18 and V36G37G38V39 both form intramolecular -sheet. Third these segments are
undergoing 13C:12C coupling meaning they are not adjacent to one another. The final constraint is
based on the small size of these peptides as well as the significant fraction of -helix this makes
formation of parallel intramolecular -sheets impossible. Based on these constraints we propose
that the monomeric A is forming a -hairpin with two -strands connected by turn structure
downstream of K16L17V18 with an N-terminal -helix (Figure 16). The turn segment is likely
stabilized by a salt bridge between D23 and K28 as predicted in other studies (201).The presence of
-helix with majority -sheet has been previously observed in A oligomers which display more
toxicity to cultured PC12 cells compared to mature fibrils which contain no -helical component
(115).
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Figure 17. The amino acid sequence of A1-42 arranged in a structure involving a b-hairpin stabilized by D23-K28 ionic
bridge, and an N-terminal stretch that may assume a-helical conformation. The isotopically labeled amino acids are
shaded. Underneath is a ribbon model for Ab monomer, composed of a -hairpin and an N-terminal -helix. The
segments K16L17V18 and V36G37G38V39 are both involved in the b-hairpin and are marked by dark blue colors.

These data also give us hints as to how these early monomers aggregate. The lack of 13C:13C
coupling exclude the possibility of parallel in-register stacking with the aggregation axis
perpendicular to hairpin plane as found in mature fibrils (Figure 17A). Stacking in an anti-parallel
arrangement would also cause 13C:13C coupling and can thus be ruled out (Figure 17B). Next we
examined oligomerization through interactions between the C-termini or N-termini of neighboring
hairpins. The lack of intermolecular -sheet signal indicates that this interaction is through non-H
bonding possibly hydrophobic or ionic. Aggregation in this manner in either a parallel (Figure
17C) or antiparallel (Figure 17D) orientation would again lead to 13C:13C coupling and therefore
61

can be confidently ruled out. We then examined dimerization through non-H bonding between the
C-termini of one hairpin strand with the N-terminus of a neighboring hairpin in either a parallel
(Figure 17E) or antiparallel (Figure 17F) manner. In this arrangement there would not be any
13

C:13C coupling matching our experimental observations and is thus not ruled out. This stacking

could take place with the -strands laterally or in a vertical manner reminiscent of steric zippers.
This vertical stacking could take place alternatively between strands (Figure 17E) or alternating
between entire hairpins (Figure 17F).
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Figure 18. Schematic models for A oligomerization through interactions between the core - hairpin structures. Two
arrows in each molecule represent two -strands, connected by a loop or turn. The monomers are colored gray and
pink, and the isotopically labeled segments are indicated by darker color. In all cases, the structures are stabilized by
intramolecular H-bonding and intermolecular non-H-bonding contacts, i.e. ionic and/or hydrophobic interactions. The
plane of the picture is parallel to the hairpin plane. In A,B the aggregation axis is perpendicular, and in C-F it is
coplanar to the picture plane.

Here we conducted FTIR on peptides 13C-labeled at specific segments in order to obtain
site-specific structural information for A1-42, ApE3-42, and their equimolar combinations. Using
this information as well as information obtained in two buffers with distinct ionic content allow us
to propose a model for an early monomer composed of a -hairpin with an N-terminal -helix.
63

Additionally, we propose that these monomers aggregate through non-H-bonding interactions
between the N-terminus of one hairpin and the C-terminus of another. These oligomers are
structurally distinct form mature fibrils and are formed via a different mechanism of aggregation.
The consistency of this data throughout repeated experiments, in spite of the polymorphic nature
of these proteins, lends credibility to these results.
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Mutual inhibition of fibrillogenesis by A peptides
Next, we sought to characterize the transitions and intermediate structures during oligomer
formation. The toxic A species is thought to be created sometime during the transition from the
-helical monomer to the mature cross-fibrils. However, it is unknown whether these oligomers
are formed as intermediates during fibrillogenesis or are formed via alternative pathways. We
sought to answer this question by examining the -to- transition of the peptides. To accomplish
this we used a novel approach, hydration from gas phase, (see methods) based on our previous use
of atmospheric humidity to induce structural changes in A (Figure 6).

Individual Peptides
Prior to examining hybrid samples we first characterized the behavior of individual
peptides. After desiccating the proteins onto the windows as described earlier, spectra of the dried
peptide was collected. These spectra indicate that both

13

CA1-42 and ApE3-42 are forming

primarily -helical structure shown by peaks at 1616 and 1657 cm-1 respectively (Figure 18). In
the 13CA1-42 spectra a shelf present ~1590 indicates presence of a small amount of -sheet and
the peak ~1673 cm-1 likely corresponds to residual TFA from peptide synthesis.
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Figure 19. FTIR spectra of 50 M ApE3-42 (red) and 13CA1-42 (blue) in HFIP added to FTIR windows followed by
HFIP removal by vacuum desiccation.

Following measurement of dried peptides structural transitions were initiated by beginning
the flow of D2O laden N2 gas into the sample chamber. The buildup of D2O within the chamber is
indicated by increasing intensity of spectral features generated by D2O stretching ~2500 (Figure
20). This data indicated that D2O saturation level reached one third of maximum after 5 minutes
and then slowly rose until maximum saturation is reached approximately 3 hours later. After the
onset of D2O hydration the peak associated with the 13CA1-42 -helix rapidly diminished while a
peak corresponding to -sheet ~1590 cm-1 quickly grew indicating a rapid initial rate of -helixto--sheet transition (Figure 21A). The peak ~1673 cm-1 is unchanged throughout hydration and
can be attributed to TFA. Hydration of the ApE3-42 caused a decrease in -helix and a
corresponding increase in -sheet content indicated by growth of a peak at 1633 cm-1 (Figure 21B).
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Over time, the reduction in -helical intensity revealed an additional peak at 1673 cm-1 which we
have previously attributed to type 1 -turns. Additionally, the A1-42 retained an amide II
absorbance while the ApE3-42 amide II was fully deuterated, as previously observed. This -to-
transition is easily observed by looking at the second derivative of the initial spectra and one after
five hours of gas phase hydration (Figure 21C,D). Examination of second derivatives reveal a
component at 1613 cm-1 in 13CA1-42, this peak indicates retention of -helical structure (Figure
21C). The downshift in wavenumber is likely due to amide dueteration throughout hydration. A
small component ~1660 cm-1 in the ApE likely corresponds to some residual -helix as well
(Figure 21D).
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Figure 20. FTIR Spectra of ApE3-42 sample in D2O absorbance region at various times of continuous injection of D2Osaturated nitrogen. The intensity of D2O asymmetric stretching vibrational-rotational mode increases as D2O vapor is
being pumped into the sample compartment of the FTIR instrument. The spectra have been stacked for clarity.
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Figure 21. FTIR spectra of 13C-A1-42 (A) and ApE3-42 (B) dried on a CaF2 window (black lines) and upon injection
of D2O-saturated nitrogen for ~5 hours (blue to red). Amide I areas have been normalized. Time points of consecutive
spectra can be determined from data of Fig. 21. The second derivatives of spectra corresponding to the dry and after
five hours of vapor hydration for the A1-42 (C) and ApE3-42 (D).

Although both peptides transitioned from -helix to -sheet the kinetics of this transition
were quite different. The ApE3-42 transition occurs much slower at first and then more rapidly later
on. To examine the kinetics of this transition we plotted A/Aas well as the height of the amide
II peak versus time (Figure 22). In the A1-42 for the first hour, the A1590/A1616 rapidly increased
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while the amide II height rapidly diminished (Figure 22A). After an hour this trend continued but
at a reduced rate. Conversely, the ApE3-42 transitions were sigmoidal in behavior. Little change
occurred in the first hour, followed by rapid change in both amide II height and A1633/A1658 (Figure
22B). The delayed -sheet formation of the ApE compared to the unmodified peptide agrees with
our previous observations.

Figure 22. Dependence of -structure formation (red) in 13C-A 1-42 (A) and ApE3-42 (B) and amide II intensities (blue)
on time of pumping D2O-saturated nitrogen into the sample compartment.

Combined Sample -to- Transition
Following measurement of the individual peptides we examined the structural effects of
combination of the peptides. Two peptide ratios were used a 9:1 (A1-42:ApE3-42) ratio and an
equimolar ratio, as we used in previous experiments. Two samples were prepared and examined
sequentially while exposed to the same vapor environment, the first has both peptides dried
together on one side of the CaF2 FTIR window, in the other sample the two peptides are dried on
opposite sides of the CaF2 window so the signal from both peptides is present in the spectra but
70

peptide interaction is not occurring (See Methods). When dried at either ratio, both A1-42 and
ApE3-42 form -helix indicated by absorbance peaks at 1617-1619 and ~1658 cm-1 respectively
(Figure 23 A,B). The -helix location is unchanged between separated and combined samples
implying a lack of

13

C:12C coupling. Therefore, we can conclude that in the -helical state the

peptides are not interacting. Curiously in all samples the

13

CA1-42 -helix absorbs at a lower

intensity than would be expected from peptide ratios.

Figure 23. FTIR spectra of the dried peptides at a 9:1 (A) and 1:1 (B) ratios. The teal spectra corresponds to separated
peptides while the green is the peptides in combination. Amide I areas have been normalized.

Both peptides when either separated or combined at a 9:1 ratio underwent -to- transition
in response to D2O vapor. After 5 hours of vapor hydration, the -helical peaks have diminished
and in their place -sheet peaks corresponding to both peptides have formed, as well as a peak at
1673 cm-1 corresponding to TFA with some likely contribution from ApE3-42 -turn (Figure
24A,B). In the separated sample the ApE3-42 -sheet was located at 1625 cm-1 while in
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combination it absorbed weaker and higher at 1639 cm-1. These peaks could normally be assigned
to inter- and intramolecular -sheet respectively. However, the high molar ratio of 13CA1-42 means
that this this upshift could also be caused by transition dipole coupling, thus further investigation
is required. Examination of the second derivative of spectra taken after 5 hours of vapor hydration
(Figure 24C,D), shows absorbance peaks at 1625 and 1639 cm-1 in both separate and combined
samples. The presence of these peaks in both samples implies that both intra- and intermolecular
-sheets are formed in both samples but co-incubation with unmodified A shifts structural
propensity of ApE from inter- to intramolecular -sheet. In

13

CA1-42 the -sheet is located at

1585 and 1587 cm-1 in separate and combined samples respectively. These peaks indicate presence
of intermolecular or cross -sheet, the small upshift in the combined sample is likely due to 13C:12C
coupling with unlabeled ApE3-42. The lack of a structural shift in the 13CA-42 is expected, due to
the high molar excess of A1-42 and the solid nature of the sample there is likely little interaction
between most A1-42 peptides and ApE3-42.
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Figure 24. FTIR spectra of ApE3-42 and 13C-A1-42 peptides at opposite sides of a CaF2 window (A) or combined on
the same side of a window (B) at a 9:1 mole ratio. Black lines are spectra of dry samples. Change in color from blue
to red corresponds to injection of D2O-saturated nitrogen for ~5 hours. Amide I areas have been normalized. Time
intervals between consecutive spectra can be determined from data of Fig. 26. C,D) Second Derivative of FTIR spectra
after 5 minutes (blue) and 5 hours (red) of hydration for both separate (C) and combined (D) peptides.

The equimolar samples also undergo -to- transition. Diminishing of the ApE3-42 -helical peak
throughout hydration again uncovers the peak located at 1673 cm-1 likely composed of both TFA
from the

CA1-42 and -turn of the ApE3-42 (Figure 25A,B). Along with this peak are peaks

13

corresponding to -sheet of both peptides. After five hours of hydration from gas phase the -sheet
peak of ApE3-42 the major peak is located at 1628 when separate and 1638 cm-1 when combined.
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When separate the A-42 -sheet peak is located at 1586 cm-1 while in combination it shifts to
1597 cm-1. For both peptides the former can be attributed to intermolecular -sheet while the latter
can be attributed to intramolecular -sheet. Examination of the second derivative of 5 hour spectra
show peaks corresponding to intra- and inter -sheets for both peptides (i.e. peaks at 1637, 1628,
1597, and 1586 cm-1) indicating that the shifted peak comes from structural shifts and not simply
13

C:12C coupling (Figure 25C,D). Additionally, these spectra contain peaks at 1656-1654 and

1617-1616 cm-1 these peaks likely represent residual -helix of ApE3-42 and A1-42 respectively,
indicating incomplete -to- transition. This data along with the data from the 9:1 ratio indicate
that ApE3-42 forms more intra- than inter-molecular -sheet in the presence of A1-42, while A142

similarly forms more intra- than inter-molecular -sheet in the presence of ApE3-42. This

relationship is demonstrated by overlaying the separated and combined samples spectra after 5
hours of D2O hydration (Figure 26).
To quantify this shift we examined the ratio Aintra/Ainter after five hours which gives the
ratio of intra to inter--sheet present in the sample, which will henceforth refer to as R. Taking
R comb/R sep allows quantification of the change in this ratio caused by peptide interaction (Table
5). The values for the 9:1 13CA1-42 are not calculated as it did not form any significant fraction of
intramolecular -sheet. For both A1-42 and ApE3-42 R comb/R sep is above 1 at both 9:1 and 1:1
ratios indicating shifts in -sheet formation caused by peptide interaction. This is compelling
evidence that the peptides act upon one another to mutually inhibit cross -sheet formation.
Curiously, the structural components are consistent with their molar ratios after hydration in both
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9:1 and 1:1 samples. This means that the altered ratios observed in dry samples is caused by a
lowered extinction coefficient for 13CA1-42 -helical structure and not improper peptide ratios.
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Figure 25. FTIR spectra of ApE3-42 and 13C-A1-42 peptides at opposite sides of a CaF2 window (A) or combined on
the same side of a window (B) at a 1:1 mole ratio. Black lines are spectra of dry samples. Change in color from blue
to red corresponds to injection of D2O-saturated nitrogen for ~5 hours. Amide I areas have been normalized. Time
intervals between consecutive spectra can be determined from data of Fig. 26. C,D) Second Derivative of FTIR spectra
after 5 minutes (blue) and 5 hours (red) of hydration for both separate (C) and combined (D) peptides.
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Figure 26. FTIR spectra for 9:1 (A) and 1:1 (B) molar ratios taken after 5 hours of continuous vapor hydration. The
teal spectra corresponds to separated peptides while the green is the peptides in combination.
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Table 4. Quantitative data describing -helix to -sheet transitions in ApE3-42 and 13C-A1-42 peptides at opposite
sides of a CaF2 window or combined together at one side of a window at 1:9 or 1:1 molar ratios.  is the shift in
wavenumbers from -helix to -sheet and  is the difference between combined and separated samples. Aintra and
Ainter correspond to the major b-sheet peaks as found experimentally and shown in the table.

9:1 (13CA1-42:ApE3-42)
ApE3-42

13

CA1-42

1:1 (13CA1-42:ApE3-42)
ApE3-42

13

CA1-42

→ Transition
Separate

1659→1625

1617→1585

1659→1628

1619→1586

34

32

30

33

Peak Shift 
-1

(cm )
Rsep (Aintra/Ainter)

0.97

0.93
0.95

Combined

1659→1639

1617→1587

1658→1638

1619→1597

Peak Shift 

20

30

20

22

1.05

1.41

Rcomb
(Aintra/Ainter)

R comb/R sep

1.08

14

2

10

11

1.11

-

1.11

1.51

The kinetics of → transition was examined by taking the ratio of the absorbance
intensity at the peaks associated with -sheet in both separated and combined samples over the
intensity of the -helical peak, and tracking it against time of hydration (Figure 27). At a 9:1 ratio
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there is very little shift in the -sheet peak of the 13CA1-42 between the separated and combined
samples as expected due to the low ratio of ApE and solid nature of the samples. When the
kinetics of -sheet formation in both separated and combined samples is examined they closely
resemble one another as well as the A1-42 individually, in that they undergo transition rapidly
initially before then slowing but continuing to transition with time. The ApE3-42 initially
underwent transition more slowly than the unmodified peptide, in agreement with previous
observations. In both separate and combined samples the ApE3-42 forms more inter- than intramolecular -sheet. However, the difference between the two narrows in combined samples
indicating a shift from inter- to intra--sheet formation (Black and white circles Figure 27 A,B).
In the 1:1 samples the kinetics are similar with A1-42 transitioning rapidly at first and then slowing
while ApE3-42 transition appeared to speed up with time (Figure 27 C,D). Examination of -sheet
formation in combination yields strong evidence that the peptides mutually inhibit intermolecular
-sheet formation in favor of intramolecular -sheet formation. For both peptides, when separated
intermolecular -sheet formation is favored while the opposite is true in combined samples (White
circles and squares are increased compared to colored in separate samples while the opposite is
true in combination). Interestingly the effect of ApE3-42 on A1-42 appeared to be most pronounced
after 3 hours, with the rate of intramolecular -sheet formation increasing greatly compared to the
formation of intermolecular -sheet.
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Figure 27. Changes in -sheet/-helix amide I intensity ratios with time of pumping D 2O-saturated nitrogen. A, B:
ApE3-42/13C-A1-42 = 1:9; C,D: ApE3-42/13C-A1-42 = 1:1. A, C: peptides are physically separated, i.e. are at opposite
sides of a CaF2 window, B, D: peptides are combined at one side of a CaF2 window. Symbols in A are identical to B,
and symbols in C is identical to D. Black graphs describe transitions in ApE3-42, red graphs describe transitions in 13CA1-42. ApE3-42 and 13C-A1-42

This data indicates that ApE3-42 and A1-42 mutually inhibit intermolecular -sheet
formation of one another, instead promoting formation of intramolecular -sheet. This data agrees
with previous observations of the ApE3-42 ability to inhibit cross -sheet formation of the A1-42
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(Figures 7,9). Kinetic data shows a decelerated rate of intermolecular -sheet formation in mixed
samples supporting this conjecture (Figure 27). Conceivably, this could be caused by intervention
of non-identical peptide molecules into structures formed by the other peptide shifting the Hbonding from intermolecular to intramolecular. Peptides forming intermolecular -sheets
eventually go on to form mature fibrils while these intramolecular -sheets likely resemble the hairpins we described earlier (Figure 16). The presence of residual -helix agrees with earlier
findings and supports this conclusion. It can therefore be concluded that A1-42 and ApE3-42
mutually inhibit formation of intermolecular -sheet, instead promoting off-pathway formation of
mixed / hairpins (Figure 28). This conclusion agrees with previous observations of delayed
fibrillogenesis of mixed samples (Figure 5).
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Figure 28. Scheme for aggregation of ApE3-42 (gray), A1-42 (red), and their combination, accompanied with an helix to -sheet transition. At the N-terminus of A1-42 there are 3 additional charges, a positive charge of the Nterminal -amino group and 2 negative charges of the side chains of Asp1 and Glu3. Helices are shown as spirals, strands as arrows, and H-bonds as black bars.

MTS Viability Assay
We next wished to examine the effect of these A hetero-oligomers on A aggregates
through collaboration with Dr. Kenneth Teter and Dr. Lucia Cilenti. In this data the most toxic
species is the equimolar combination of ApE3-42 and A1-42 at two hours of aggregation (Figure
29). This is the time period where the greatest population of hetero-oligomer is thought to exist.
This data demonstrates the enhanced cytotoxic properties of these hetero-oligomers.
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Figure 29. Change in cellular viability caused by A aggregates as demonstrated by MTS assay. Studies were
conducted in triplicate and normalized so that the control is equivalent to 100% viability. A peptides were added to
peptides at a final concentration of 10 M for 28 or 50 hours. Ab peptides that had been aggregating in PBS at 37°C
for 2 hours (First group) 4 hours (second group) and 24 hours (final group)

A Mediated Membrane Calcium Leakage
The formation by A of calcium permeable membrane pores is a hypothesized mechanism
of A mediated cytotoxicity in AD. To examine the effect of these oligomers, A aggregates were
added to a solution containing calcium bound in unilamellar lipid vesicles composed of 60% POPC
30% POPG and 10% cholesterol after 2 and 24 hours of aggregation. The release of calcium from
vesicles was demonstrated via increase in fluorescence of Quin-2. Maximum fluorescence is
demonstrated by popping all of the vesicles with triton-X. The results of this are striking, at two
hours of aggregation A1-42 does not induce any greater calcium release than buffer control.
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However, ApE3-42 as well as 9:1 and 1:1 combinations induce significant release of calcium
(Figure 30A). At 24 hours of aggregation the combinations had a lesser effect than at two hours,
consistent with pore formation by oligomers but not mature fibrils (Figure 30B). Curiously, the
ApE3-42 actually had a greater effect on calcium release at 24 hours than 2 hours. Additionally, at
24 hours the 9:1 had a greater effect than the 1:1.

Figure 30. Vesicular calcium release as assayed by Quin-2. A peptides were added to vesicles after 2 hours (A) and
24 hours (B) of aggregation via stirring at 37 °C. Data for release via A1-42 (blue), ApE3-42 (red), 9:1 (green) 1:1 (teal)
and buffer control (black) are shown. Peptides were added following two measurements to establish a baseline, 0.5%
Triton X-100 was added to the control after 6 measurements to disrupt vesicles and measure maximum fluorescence.

This data demonstrates that these hetero-oligomers do in-fact induce a significant drop in
cellular viability compared to individual peptides. These hetero-oligomers also induced greater
release of intra-vesicular calcium. The far greater effect of ApE3-42 at 24 hours as well as the
greater effect of 9:1 than 1:1at 24 hours, is not consistent with toxicity data. To confirm these
results follow up studies are being conducted. If confirmed, this data implies that formation of
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calcium pores in lipid membranes may not be the primary A-mediated pathway of cellular
dysfunction in AD.
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CHAPTER FIVE: CONCLUSIONS
Recent evidence has shifted focus from fibrillar to soluble oligomeric species of A as the
primary cytotoxic species in AD. Due to the difficulty of their study, namely their structural
heterogeneity, dynamics, and polymorphic nature, little is known about the structure and formation
of A oligomers. Pyroglutamylated A are major species of A in the AD brain displaying
increased toxicity. Studies have demonstrated the ability of ApE3-42 to increase the toxicity of
unmodified A in low molar ratio through structural changes however, little is known about the
mechanism.
This project sought to investigate A oligomer structure. In particular we aimed to examine
the structural effect of ApE on unmodified A. Current evidence implicates these oligomers as
the cytotoxic A agent in AD (38, 46). Pyroglutamylated A species make up a significant fraction
of the soluble A in AD brains. ApE3-42 has been demonstrated to cause significant changes to
oligomers of A1-42 and ApE3-42, altering both their structure and toxicity, even when it is present
in low molar ratio (44). We first sought to examine the effects of ApE3-42 on the structure and
fibrillization kinetics of A1-42. Data collected via CD indicate that ApE3-42 delays -sheet
formation of the unmodified peptide in mixed samples. TEM images of the unmodified A
collected after two hours of aggregation contain mature fibrils while samples of ApE and mixed
samples contained greater numbers of globular aggregates. FTIR data indicates that ApE inhibits
cross-sheet formation of the unmodified peptide, thus retarding fibrillogenesis. Inhibiting fibril
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formation may increase the population of A oligomers or promote formation of off-pathway
aggregates of enhanced toxicity.
We next sought to characterize the early oligomers of ApE and unmodified A as well as
the structural changes upon co-incubation. To further investigate the structure of A oligomers we
utilized peptides selectively

13

C-labeled at two specific segments K16L17V18 and V36G37G38V39.

These allow site specific determination of protein secondary structure. Data was collected of A142,

ApE3-42, and, their equimolar combination labeled at two locations and in two buffers of

different ionic content. This data indicates that early oligomers are composed of -helix,
intramolecular -sheet, and -turn structure, and that the labeled segments were forming sheets.
Changes in -helical content in different buffer conditions indicate that the a-helix is located at
the N-terminus. Additionally, the carbon coupling of labeled residues indicates a lack of 13C:13C
coupling giving both tertiary and quaternary structural insight. These data allow us to propose a
possible structure for the monomeric A namely a -hairpin with an N-terminal -helix and a turn occurring downstream of K16L17V18. Data indicates that oligomerization likely occurs through
non H-bonding interactions between neighboring -hairpin strands.
After structural characterization of early peptides we sought greater detail on the early
dynamics of oligomerization. In the plasma membrane as well as HFIP A peptides are -helical.
In buffer they quickly form -sheets and begin to aggregate. We have already observed that ApE342

inhibits this -sheet formation of the A1-42 in aqueous buffer. To observe these changes we

gradually hydrated the peptides using D2O vapor. Upon exposure to vapor both peptides undergo
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-to- transition but with different kinetics. A1-42 transitions rapidly in the first hour and
continued to transition slowly afterwards, while ApE3-42 transitioned in a sigmoidal manner. When
combined the peptides exerted a mutual effect upon one another to intermolecular -sheet
formation instead forming intramolecular -sheets. Data from vesicle calcium release studies and
MTS assays indicate that in combination the peptides have a more pronounced effect on cellular
viability than the peptides individually and induce greater release of calcium than the unmodified
peptide alone. Thus hybrid ApE and unmodified samples exhibit enhanced cytotoxicity possibly
due to increased formation of off pathway mixed / oligomers instead of the intermolecular sheet structures that make up mature fibrils. These hetero-oligomers induce greater calcium release
from lipid membranes and exert a greater effect on cellular viability than the unmodified A.
Previous studies on A oligomers have found an antiparallel orientation while studies on
mature fibrils show a parallel in-register orientation. In FTIR spectra antiparallel -sheet is
indicated by a major peak 1636-1630 cm-1 and a minor peak 1680-1670 cm-1. Although several
spectra appear to contain a peak corresponding to antiparallel -sheet (Figures 6, 16A,B), the low
intensity of this peak makes it impossible to differentiate from other structural components. In
ApE3-42 this peak is located in a similar location to -turn and TFA while in 13CA1-42 this peak
(~1643-1633 cm-1) corresponds with ApE3-42 -sheet absorbance. Therefore, it is not possible to
determine whether these oligomers are in a parallel or antiparallel orientation. Curve fitting of
spectra indicate that -helical and -sheet fractions of peptides vary to a degree (Tables 3,4). This
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indicates low barrier energy between these structures; and represents a possible source of A
polymorphism.

Significance
It is believed that the toxic A species in AD is formed during the transition from the helical structure formed prior to lipid membrane exit to the intermolecular -sheet structure found
in mature fibrils. Here we characterized this transition as well as proposing a data-based model of
early A monomers as well as aggregation. Data indicate that A1-42 and ApE3-42 mutually inhibit
cross--sheet formation of one another instead forming mixed / hairpins. Inhibition of cross sheet formation delayed fibrillogenesis and lead to an increase in the population of globular
aggregates. Studies have found oligomers of mixed / content to display enhanced cytotoxicity
(114-116). These hetero-oligomers had a greater effect on the viability of PC12 cells than either
peptide alone indicating their potent effect. Additionally, vesicle calcium release assays
demonstrate that this effect may in part be due to enhanced formation of calcium permeable pores
in lipid membranes. This work highlights the importance of hetero-oligomers in the pathogenesis
of AD. This data gives insight into oligomer structure and formation as discussed in figure 1
(Figure 31).
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Figure 31. Update of Figure 1 using data collected during this work. Mixed populations of Ab1-42 and AbpE3-42
promote formation of hetero-oligomers via a non-fibrillogenic pathway. These oligomers display increased
cytotoxicity to PC12 cells possibly through the formation of calcium permeable membrane pores leading to loss of Ca
2+
homeostasis.

Future Studies
Targets for future study include A1-40 and its pyroglutamylated counterpart the ApE3-40.
In vivo A populations are heterogeneous but little is known about the behavior of mixed peptide
populations. These species are prevalent in the AD brain and examination should be conducted on
whether they have similar structural effects upon one another. If they possess the same mutual
inhibitory relationship, it is strong evidence that this effect may occur with other pyroglutamylated
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A species. We also seek a method to stabilize oligomers for the time scales necessary for ssNMR
analysis. Of particular interest is stabilization of oligomers formed in physiologically relevant
conditions without using methods that may induce structural changes. High resolution structural
data from ssNMR would represent strong supporting evidence for the -hairpin model proposed
here. Follow-up studies should also be conducted to investigate inconsistencies between vesicular
calcium release and cellular viability studies.
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APPENDIX A: PEAK FITTING OF DRY SPECTRA
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Peak fitting of Dry FTIR spectra. The original spectra (blue), peak fit (dotted red), and baseline
(black) are shown. Fit peaks corresponding to alpha helix (orange) and the labeled segment (pink)
are also shown. Peaks shown in grey are considered other in area concentration and correspond
primarily to unordered structure. Peaks corresponding to side chain interactions are dotted grey
and are not included in area calculations.
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APPENDIX B: PEAK FITTING UNLABELED PEPTIDES
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. Peak Fit Spectra of A1-42 ApE3-42 and their equimolar combination in 10 mM phosphate pD
6.8 buffer labeled here as low salt as well as 50 mM phsosphate 50 mM NaCl pD 6.8 labeled here
as high salt for 10, 60, and 120 minutes. The experimental measurement is shown in Blue while
the Red dotted line is the sum of all components, fit peaks correspond to turn (green), -helix
(orange), and -sheet (purple) unattributed peaks are shown in grey and are primarily composed
of unordered structure. Peaks corresponding to side chain interactions are shown in dotted grey
and are not included in area calculations. The second derivative of the experimental spectra is
shown in black underneath. Total peptide concentration is 50 M.
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APPENDIX C: PEAK FITTING OF LABELED PEPTIDES
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. Curve fit spectra of

13

C-labeled A1-42, ApE3-42 and their equimolar combination in 10 mM

phosphate pD 6.8 buffer (low salt conditions) as well as 50 mM phsosphate 50 mM NaCl pD 6.8
(physiological buffer) for 10, 60, and 120 minutes. Peptides were 13C- and 15N-labeled at either
K16L17V18 or V36G37G38V39.The experimental measurement is shown in Blue while the Red dotted
line is the sum of all components, fit peaks correspond to turn (green), -helix (orange), and sheet (purple) unattributed peaks are shown in grey and are primarily composed of unordered
structure. Peaks corresponding to side chain interactions are shown in dotted grey and are not
included in area calculations. The second derivative of the experimental spectra is shown in black
underneath. Total peptide concentration is 50 M.
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Table 5. Distribution of secondary structures in 50 mM phosphate 50 mM NaCl pD 6.8 as calculated by curve fitting.
Numbers are the averages at 10, 60, and 120 minutes in buffer, label combination refers to the fraction of the peak
corresponding to the 13C-label in KLV/VGG and VGGV/KLV spectra. Components counted as other, primarily
unordered structure, are not included in the table.

High Salt

A1-42

ApE3-42

1:1

-turn

19.5 ± 8.3

27.7±5.0

22.1±3.5

-helix

24.4±10.7

18.1±10.6

26.9±7.2

-sheet

41.1±5.0

45.4±5.6

36.2±10.8

C-Label KLV

7.4±1.0

8.0±1.5

5.8±0.7

C-Label VGGV

10.3±0.8

9.9±0.4

10.4±0.5

C-Label Combination

-

-

6.1±2.8

13

13

13

126

Physiological Buffer
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130
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Low Salt Conditions
Table 6. Distribution of secondary structures in 10 mM phosphate pD 6.8 as calculated by curve fitting. Numbers are
the averages at 10, 60, and 120 minutes in buffer, label combination refers to the fraction of the peak corresponding
to the 13C-label in KLV/VGG and VGGV/KLV spectra. Components counted as other, primarily unordered structure,
are not included in the table.

Low Salt

A1-42

ApE3-42

1:1

-turn

26.2±5.2

21.3±3.6

25.0±5.5

-helix

21.8±7.9

21.5±8.1

15.3±6.0

-sheet

34.2±9.5

35.2±10.2

36.5±8.5

C-Label KLV

4.9±0.6

6.7±0.5

6.3±0.6

C-Label VGGV

7.4±0.4

12.9±0.4

14.2±0.2

C-Label Combination

-

-

8.2±1.3

13

13

13
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